US20100191103A1 - Apparatus and method for surgical bypass of aqueous humor - Google Patents
Apparatus and method for surgical bypass of aqueous humor Download PDFInfo
- Publication number
- US20100191103A1 US20100191103A1 US12/720,543 US72054310A US2010191103A1 US 20100191103 A1 US20100191103 A1 US 20100191103A1 US 72054310 A US72054310 A US 72054310A US 2010191103 A1 US2010191103 A1 US 2010191103A1
- Authority
- US
- United States
- Prior art keywords
- tract
- aqueous humor
- vein
- tissue
- distal end
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000001742 aqueous humor Anatomy 0.000 title claims abstract description 36
- 238000000034 method Methods 0.000 title abstract description 30
- 210000003462 vein Anatomy 0.000 claims abstract description 54
- 210000001519 tissue Anatomy 0.000 claims abstract description 52
- 239000000463 material Substances 0.000 claims abstract description 29
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 7
- 229920002674 hyaluronan Polymers 0.000 claims description 7
- 229960003160 hyaluronic acid Drugs 0.000 claims description 7
- 238000002059 diagnostic imaging Methods 0.000 claims description 6
- 230000003287 optical effect Effects 0.000 claims description 6
- 239000003146 anticoagulant agent Substances 0.000 claims description 4
- 229960004676 antithrombotic agent Drugs 0.000 claims description 4
- 230000004663 cell proliferation Effects 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 229910001000 nickel titanium Inorganic materials 0.000 claims description 4
- 238000002604 ultrasonography Methods 0.000 claims description 4
- 238000011065 in-situ storage Methods 0.000 claims description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 2
- 229960002897 heparin Drugs 0.000 claims description 2
- 229920000669 heparin Polymers 0.000 claims description 2
- 229960000485 methotrexate Drugs 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 2
- 229960002930 sirolimus Drugs 0.000 claims description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 claims description 2
- 238000012014 optical coherence tomography Methods 0.000 claims 1
- 210000002159 anterior chamber Anatomy 0.000 abstract description 29
- 208000002352 blister Diseases 0.000 abstract description 9
- 239000012530 fluid Substances 0.000 abstract description 6
- 208000010412 Glaucoma Diseases 0.000 abstract description 5
- 230000008569 process Effects 0.000 abstract description 2
- -1 polyethylene Polymers 0.000 description 10
- 238000003384 imaging method Methods 0.000 description 9
- 238000001356 surgical procedure Methods 0.000 description 8
- 239000007943 implant Substances 0.000 description 7
- 238000013459 approach Methods 0.000 description 6
- 230000004410 intraocular pressure Effects 0.000 description 5
- 239000013307 optical fiber Substances 0.000 description 5
- 230000000149 penetrating effect Effects 0.000 description 5
- 239000000835 fiber Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 210000001585 trabecular meshwork Anatomy 0.000 description 4
- 238000012800 visualization Methods 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 3
- 239000004642 Polyimide Substances 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- 229910000831 Steel Inorganic materials 0.000 description 3
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 3
- HZEWFHLRYVTOIW-UHFFFAOYSA-N [Ti].[Ni] Chemical compound [Ti].[Ni] HZEWFHLRYVTOIW-UHFFFAOYSA-N 0.000 description 3
- 229910045601 alloy Inorganic materials 0.000 description 3
- 239000000956 alloy Substances 0.000 description 3
- 230000003510 anti-fibrotic effect Effects 0.000 description 3
- 210000000795 conjunctiva Anatomy 0.000 description 3
- 238000002224 dissection Methods 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 3
- 229920002492 poly(sulfone) Polymers 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 229920001721 polyimide Polymers 0.000 description 3
- 239000004926 polymethyl methacrylate Substances 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 239000004810 polytetrafluoroethylene Substances 0.000 description 3
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 3
- 239000010959 steel Substances 0.000 description 3
- 239000010936 titanium Substances 0.000 description 3
- 229910052719 titanium Inorganic materials 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 239000012781 shape memory material Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000012876 topography Methods 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 1
- 229920001410 Microfiber Polymers 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 206010030348 Open-Angle Glaucoma Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229910001069 Ti alloy Inorganic materials 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004240 ciliary body Anatomy 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 210000002555 descemet membrane Anatomy 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000005350 fused silica glass Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000001232 limbus corneae Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000003658 microfiber Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/00781—Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment
Definitions
- Glaucoma is a disease condition of the eye in which increased intraocular pressure (IOP) is created by dysfunction in the drainage mechanism for the aqueous humor.
- IOP intraocular pressure
- Aqueous humor is produced within the eye in the ciliary body and flows within the anterior region of the eye.
- the aqueous humor normally flows through a network of tissues at the interior angle of the anterior chamber, named the trabecular meshwork and subsequently into a circular drainage space named Schlemm's canal.
- Schlemm's canal a circular drainage space
- the aqueous humor continues its drainage path into collector channels and finally into aqueous veins to enter the venous system.
- aqueous humor typically in open angle glaucoma, the pathway for aqueous humor becomes narrowed or occluded, increasing IOP and resulting in gradual nerve damage and loss of vision. Such conditions are usually treated by topical drugs in the form of eye drops, but may result in surgical treatment if drug treatment becomes ineffective or if patient compliance is an issue.
- Traditional glaucoma surgery such as trabeculotomy or trabeculectomy, involves dissection of the eye and the forming of new holes through the trabecular meshwork portion of the drainage pathway. The fluid is channeled to a reservoir formed under the conjunctiva known as a bleb. While blebs are effective in removing the aqueous humor, bleb complications present the highest incidence of post-surgical complications due to irritation and infection.
- a new class of surgical procedures aims to approach treatment of the ocular drainage system from the scleral tissues without penetrating the interior chamber of the eye. These procedures are termed “non-penetrating” surgery and involve careful surgical dissection of the scleral tissues to access the tissues involved with ocular drainage. Deep sclerectomy is a form of this type of procedure in which a portion of intrascleral tissue is removed nearly to Descemet's membrane to allow significant aqueous flow from the anterior chamber to a bleb. Viscocanalostomy is another non-penetrating procedure, which increases the flow of aqueous humor form the anterior chamber into a surgically created intrascleral lake. Although non-penetrating procedures present fewer direct complications than traditional surgeries, most of the procedures still require the surgical dissection of ocular tissues and a high level of surgical skill.
- the invention provides an apparatus for creating a tract within the scleral tissues of an eye comprising an elongated body portion shaped to create a tract which forms a path for flow of aqueous humor into an ocular vein.
- the elongated body portion has a proximal end and a distal end.
- the distal end may comprise a mechanically cutting tip or an energy source to ablate tissue.
- the distal end may be visible by medical imaging methods such as ultra sound, or optical coherence topography or visible under direct observation by an optical beacon at the tip.
- the apparatus may additionally accommodate a space-maintaining material for placement within the tract, such as hyaluronic acid or a cell proliferation inhibitor. These space-maintaining materials may also comprise a stent device made of hyaluronic acid, nickel, titanium alloy or other material.
- the invention also provides a method for creating a path for flow of aqueous humor of the eye into an ocular vein comprising;
- the source of aqueous humor typically will comprise the anterior chamber, Schlemm's canal, the collector channel or a bleb.
- FIG. 1 Sectional view of the anterior portion of the human eye.
- FIG. 2 Cross-sectional view of the drainage system in the human eye.
- FIG. 3 Cross-sectional view of the drainage system in the human eye showing a microsurgical tool and tissue tract from an episcleral vein to the anterior chamber.
- FIG. 4 Cross-sectional view of the drainage system in the human eye showing tissue tract from an episcleral vein to Schlemm's canal.
- FIG. 5 Cross-sectional view of the of an embodiment of the invention comprising a microcannula assembly.
- FIG. 6 View of an embodiment of a microcannula assembly incorporating fiber optic core for transmission of energy from a source.
- FIG. 7A View of an embodiment of the invention comprising tube-stent devices.
- FIG. 7B View of a stent device comprising alternating filament loops.
- FIG. 8A Sectional view of the anterior portion of the human eye showing bypass implant comprising shape memory material incorporating a reduced diameter segment to maintain flow control at a minimum level.
- FIG. 8B Sectional view of the anterior portion of the human eye showing laser energy being applied externally to increase the diameter of the shape memory bypass implant.
- FIG. 9 Cross-sectional view of microcannula assembly incorporating a detachable tube stent as the distal sheath of the assembly.
- FIG. 10A Sectional view of the anterior portion of the human eye showing detachable tube stent assembly creating tract from an episcleral vein to the anterior chamber.
- FIG. 10B Sectional view of the anterior portion of the human eye showing tube stent in place after removal of the cannula assembly.
- the present invention to provide minimally invasive microsurgical tools and methods, which enable surgical creation of a tissue tract within the tissues of the eye to directly connect a source of aqueous humor such as the anterior chamber, to an ocular vein, thereby forming a shunt or bypass for aqueous humor.
- a source of aqueous humor such as the anterior chamber
- the aqueous veins, into which aqueous humor normally drains, are good candidates for this procedure, however the invention is not limited to these specific vessels.
- the tissue tract from the vein may be connected to any source of aqueous humor, including the anterior chamber, an aqueous collector channel, Schlemm's canal, or a drainage bleb. Since the aqueous humor passes directly into the venous system, the normal drainage process for aqueous humor is restored.
- the tools and methods effectively bypass the small anatomical structures of the drainage system, such as the trabecular meshwork, Schlemm's canal and the collector channels, which have been identified with the mechanism of glaucoma. Furthermore, the invention describes devices and materials that can be implanted in the tract to maintain the tissue space and fluid flow post operatively.
- FIG. 1 shows a sectional view of the anterior portion of the human eye for reference.
- the invention involves the steps of: firstly, identifying a candidate vein 4 on or within the eye of a living subject; secondly, inserting one or more tools into the eye to create a tissue tract in the sclera 3 , that connects the vein to a source of aqueous humor such as the anterior chamber of the eye 1 , or Schlemm's canal 2 ; thirdly, optionally inserting an implant or material to maintain the tract opening and fluid flow, and; lastly, closing the surgical access site as required.
- the tools and materials comprise the apparatus to create a tissue tract within scleral tissues of the eye such that the tract acts as a fluid path for aqueous humor to the vein.
- FIG. 2 A magnified cross-sectional view of the drainage system of the human eye is shown in FIG. 2 for reference.
- An episcleral vein 4 is identified suitable for creating the bypass.
- Candidate vessels can be found close to the surface of the eye, such as but not limited to, conjunctiva veins, anterior ciliary veins, and episcleral veins. Surface vessels can be directly visualized and accessed while subconjunctival vessels may require a small incision in the conjunctiva for access.
- Subsurface vessels such as collector channels 5 and aqueous veins 6 can be identified by high-resolution medical imaging methods such as high frequency ultrasound (HFU) or optical coherence topography (OCT). The use of medical imaging is preferred in that veins which are in the most surgically desired location, can be selected.
- HFU high frequency ultrasound
- OCT optical coherence topography
- Vessels which are angled toward the anterior chamber 1 , or Schlemm's canal 2 , and having appropriate dimensions and minimal tortuosity, can be identified as candidates for bypass.
- Doppler imaging can be used to assist identification of candidate blood vessels.
- Pressure changes applied to the anterior chamber will also facilitate vein identification and selection by distinguishing vessels with the most direct connection to the aqueous drainage system. In some situations the blood/aqueous interface can be seen in episcleral veins. Changes in pressure in the chamber will cause this interface to move forward and backward within the vein. Furthermore, pressure changes can result in a change of the apparent vein diameter, which can be directly observed.
- FIGS. 3 and 4 Cross-sectional views of the drainage system of the human eye with a surgically created tissue tract are shown in FIGS. 3 and 4 for reference.
- the use of HFU or OCT imaging is desired to determine the optimal placement of the tissue tract 7 , from the candidate vein to the anterior chamber 1 , or if desired, to a collector channel, Schlemm's canal 2 , or an existing bleb.
- any region of the anterior chamber in proximity to the vein may be used including the area at the anterior segment angle and the corneal-scleral junction.
- the surgeon may use imaging techniques to pre-plan the route of the surgery and to verify locations, direction and placement of the microsurgical tool 8 , during the procedure.
- the method may comprise first access to a vein 4 , and then creating a tract 7 , toward and into a source of aqueous humor such as the anterior chamber 1 .
- the method may comprise access from the anterior chamber first, and then through the subsurface tissues to a vein.
- the advantage of such a method is that the tissue penetration may be accomplished through clear cornea, starting 180° from the bypass point and transversing through the anterior chamber.
- the microsurgical tool is placed at the correct site for penetration of the tissues through to the candidate vein. Small, clear corneal incisions are self-sealing and therefore do not require closure mechanisms. If the initial penetration of the tool into the eye is elsewhere, then the entry inscision may need to be closed after removal of the tool.
- the microsurgical tool may comprise an elongated tool, such as a microcannula, with a tip at one end which is directed into a vein.
- This may be a mechanically cutting tip such as a solid or hollow trocar-like member capable of creating a tunneled tract of controlled diameter through scleral tissues.
- the tool may comprise a hollow tube with a sharpened distal edge used to core out a tissue tract. The removal of tissue may promote the subsequent stability of the tract and aid placement of an implant device into the channel.
- the tool may comprise an outer sheath 11 and inner member, with the outer sheath disposed axially about the inner member.
- the inner member may comprise a trocar 10 , solid rod, hollow rod or cylinder, needle, wire or optical fiber.
- the inner member may be designed to allow exchange during use to allow specific functions to be brought to the tip of the tool once it is located in tissue.
- the microcannula may be handled at its proximal end by a suitable accommodating mechanism such as luer fitting 12 .
- an optical fiber inner member may be used to carry visible light to the tip of the fiber 13 , which may be disposed to reside at the tip of the sheath and hence may be used for direct visualization of the location of the tool through scleral tissues.
- a cutout section or window near the distal tip of the sheath may be provided to visualize the optical fiber tip.
- the optical fiber may be fabricated from glass, fused silica, or plastic that is optically transparent to the wavelength of light used for visualization.
- the described optical beacon can provide an adjunct method of tracking the creation of the tract, aiding HFU or OCT imaging.
- the optical fiber may be used to carry energy for tissue ablation such as laser energy, in order to create the tract.
- the tip may also accommodate transmission of radio frequency or thermal energy to ablate or coagulate tissue.
- the fiber optic line 14 is connected to energy source 15 .
- the microsurgical tool is sized appropriate for access through small vessels and to create controlled diameter tissue tracts. Diameters from 50-500 microns are useful, and in particular diameters from 50-200 microns are preferred. Outer diameter of a sheath member may correspond to these ranges and may comprise a wall thickness between 10 and 100 microns.
- the microsurgical tool can comprise a flexible microcannula to allow the distal tip to be advanced within the vein toward a source of aqueous humor such as the anterior chamber.
- the microsurgical tool may be fabricated from structural materials such as metals including steel, titanium, and nickel-titanium alloys, structural polymers including polyimide, polyethylene, polyamide, polypropylene, polystyrene, polymethylmethacrylate, polytetrafluoroethylene, and polysulfone.
- structural materials such as metals including steel, titanium, and nickel-titanium alloys, structural polymers including polyimide, polyethylene, polyamide, polypropylene, polystyrene, polymethylmethacrylate, polytetrafluoroethylene, and polysulfone.
- Several tools with different material composition and design may be used sequentially in the surgical procedure. For example, one tool may be used to access the vessel and exchanged with a tool to create the scleral tissue tract.
- different types of inner members such as for cutting or light conduction may be used interchangeably within an outer sheath.
- the tool will accommodate features for orientation of the tract identified and controlled by the clinical practitioner.
- the use of medical imaging to coordinate or verify the position and orientation of the tract aids accuracy and precision of tract placement.
- Tools which are in the field of view of the imaging system allow for identification of the tool's position while minimizing the creation of artifacts into the image.
- Selection of tool material and/or the use of contrast markers can provide the desired imaging properties for the tools.
- the tract created may optionally be filled with a material to help maintain the patency and fluid flow of the tract.
- a material may comprise an anti-fibrotic material, anti-thrombotic agent, space maintaining material, tube-like stent or similar device to assure that the drainage tract remains patent.
- Anti-fibrotic materials such as hyaluronic acid and cellular proliferation inhibitors such as methotrexate, sirolimus, and paclitaxel, may be applied or released from a device within the tract.
- Anti-thrombotic agents such as heparin and tissue plasminogen activator may also be applied or released from a device within the tract.
- Such materials may be in the form of microspheres, microparticles, microfibers, open-or closed-cell matrices, foams, gels and tubes, which may be designed to change their configuration in-situ after implantation.
- the materials may comprise degradable materials such as hyaluronic acid, collagen , glycosoaminoglycans and degradable synthetic polymers.
- the materials may also comprise non-degradable materials with biocompatibility suitable for implant use including metals such as steel, titanium, and nickel-titanium alloys, and polymers such as polytetrafluoroethylene, polymethylmethacrylate, polyimide, polyethylene, polypropylene and polysulfone.
- a tubular stent-like device may be placed within the tract to enlarge the tract diameter or provide stabilization through mechanical means.
- FIG. 7 a there are examples shown of a simple tube 16 and a fenestrated tube 17 .
- the outer sheath of the microsurgical tool may comprise a tube-stent, and can be left behind after the tool core is removed.
- FIG. 9 there is shown such a microcannula assembly comprising a trocar tip core 10 , the detachable stent 22 , driving cannula 23 , and handle 24 .
- the tube-stent may be pre-sized based on pre-surgical imaging or may be designed to be cut to size prior to or after implantation.
- the venous end of the tube-stent may be implanted to reside in the vein or further advanced to reside in a collector channel.
- the tube-stent may reside in the entire tissue tract between the vein and the aqueous humor source, or a portion of the tract. Several discrete tube-stents may also be used in stabilizing the tissue tract.
- the diameter of the tube-stent may be designed to allow expansion in-situ, for example, by hydraulic pressure or thermal energy, or through the use of shape memory materials for construction of the tube-stent.
- a laser 20 is used to increase the diameter of a shape memory implant 21 .
- tube-stents designed to be conformable to the tissue tract and that do not create mechanical loads on the tissue other than for dilation of the tract. Mechanical features of the tube-stent such as tissue interfacing porosity may be incorporated to aid retention.
- Tube-like stents may be comprised of permanent or biodegradable materials.
- Suitable materials include metals such as steel, titanium and nickel titanium alloys, and biocompatible polymers such as hyaluronic acid, collagen, glycosoaminoglycans, polylactic acid, polyglycolic acid, polytetrafluoroethylene, polymethylmethacrylate, polyimide, polyethylene, polypropylene and polysulfone
- the tube-stent device can also have a design to provide a controlled amount of flow restriction that would limit retrograde flow of blood.
- Devices with different flow resistance may be fabricated and chosen for optimization of aqueous flow by the practitioner.
- a shape memory stent incorporating a reduced diameter segment 19 connects the anterior chamber 2 with an episcleral vein 4 via entry point 9 .
- a valve may be incorporated into the tube stent to limit retrograde flow or to set a threshold pressure for flow.
- the flow characteristics of the tube-stent may be varied after the procedure upon examination of the patient's IOP.
- Various energy sources such as laser light, RF or microwave may be directed at a portion of the implant to dilate or contract discrete segments to control flow.
- a photoreactive polymer or a pre-stressed polymer similar to heat shrink tubing may be employed to perform this function.
- the stent-like device may comprise a series of filaments or wires.
- the device may be formed as a woven tube or a series of filament loops 18 .
- the filament loops may be attached to each other in an alternating, or “zigzag” pattern, or may be attached to a linear member along one axis.
- the loops may be disposed at an angle to the axis, and be sufficiently flexible to maintain the tract opening without creating undue stress upon the surrounding tissues.
- Such an embodiment allows for the stent device to conform to changes in diameter or direction of the tract.
- the invention also provides methods to surgically create an aqueous bypass in the eye.
- the following methods are provided as explanatory and do not constitute the entire scope of methods which may be used in conjunction with the microsurgical tools described herein.
- the surgeon will visually identify a candidate vein 4 on or about the surface of the eye.
- a pathway from a target point along the axis of the vein to the desired endpoint, such as the anterior chamber 2 is mapped.
- a surgical tool comprising a handle 24 , tube stent sheath 22 , and trocar is used.
- the trocar has a distal point configured to pierce the tissues.
- the tube-stent will be of correct length to connect the chamber and vein.
- the vein is cannulated with the tool at the target point, and the tool oriented in the angle and direction that was plotted from the imaging session.
- the tool is advanced along the pathway until the tip is seen penetrating the anterior chamber at entry point 9 , preferably above the iris.
- the trocar inner member and the tool are removed, leaving the tube-stent 22 behind.
- a syringe containing an antifibrotic hydrogel can be attached to the proximal end of the sheath.
- the hydrogel is applied into the tract at the same time that the tool, including the sheath, is being withdrawn, to aid in maintaining the tract.
- the access site is then sealed by any requisite surgical method.
- an episcleral vein is located by visualization through a surgical microscope.
- a target point is designated along the vein, at a distal point of sufficient diameter to accept the incoming microsurgical tool.
- An entry point is determined along the corneal limbus approximately 180° away from the candidate vein.
- a gonio lens is used to visually inspect the anterior angle at the bypass site to choose a target entry point to connect to the vein.
- the microsurgical tool in this instance comprises a fiber optic inner member with a trocar like distal tip and an outer member comprising a tube-stent of the correct length to connect the chamber and vein. The tool is advanced through the clear cornea at the entry point and advanced across the anterior chamber to the tissue entry point. The tool is then advanced through the tissues guided toward the candidate vein by visualization of the beacon tip of the tool.
- the tool is advanced until the distal tip enters the vein and then continued until a sufficient portion of the tube stent distal end is within the vessel to maintain flow. If sized correctly, the proximal end of the tube stent will now reside just within the anterior chamber. The tool is withdrawn, leaving the tube stent behind. The entry point may be surgically closed or allowed to self-seal.
- the procedure may also be performed on more than one venous site per eye as may be required to provide adequate drainage.
- the procedure may be performed on one site, and the patient's IOP monitored post-surgically. If more pressure reduction is required, then a subsequent procedure may be performed at another target site. Multiple drainage paths can thereby be created.
Abstract
The invention provides minimally invasive microsurgical tools and methods to form an aqueous humor shunt or bypass for the treatment of glaucoma. The invention enables surgical creation of a tissue tract (7) within the tissues of the eye to directly connect a source of aqueous humor such as the anterior chamber (1), to an ocular vein (4). The tissue tract (7) from the vein (4) may be connected to any source of aqueous humor, including the anterior chamber (1) ), an aqueous collector channel, Schlemm's canal (2), or a drainage bleb. Since the aqueous humor passes directly into the venous system, the normal drainage process for aqueous humor is restored. Furthermore, the invention discloses devices and materials that can be implanted in the tissue tract to maintain the tissue space and fluid flow.
Description
- This application claims priority of U.S. Provisional Patent Application No. 60/411,668 (Attorney Docket No. ISC1P003P), filed 17 Sep. 2002, which application is incorporated herein by reference in its entirety for all purposes.
- Glaucoma is a disease condition of the eye in which increased intraocular pressure (IOP) is created by dysfunction in the drainage mechanism for the aqueous humor. Aqueous humor is produced within the eye in the ciliary body and flows within the anterior region of the eye. The aqueous humor normally flows through a network of tissues at the interior angle of the anterior chamber, named the trabecular meshwork and subsequently into a circular drainage space named Schlemm's canal. The aqueous humor continues its drainage path into collector channels and finally into aqueous veins to enter the venous system.
- Typically in open angle glaucoma, the pathway for aqueous humor becomes narrowed or occluded, increasing IOP and resulting in gradual nerve damage and loss of vision. Such conditions are usually treated by topical drugs in the form of eye drops, but may result in surgical treatment if drug treatment becomes ineffective or if patient compliance is an issue. Traditional glaucoma surgery, such as trabeculotomy or trabeculectomy, involves dissection of the eye and the forming of new holes through the trabecular meshwork portion of the drainage pathway. The fluid is channeled to a reservoir formed under the conjunctiva known as a bleb. While blebs are effective in removing the aqueous humor, bleb complications present the highest incidence of post-surgical complications due to irritation and infection.
- A new class of surgical procedures aims to approach treatment of the ocular drainage system from the scleral tissues without penetrating the interior chamber of the eye. These procedures are termed “non-penetrating” surgery and involve careful surgical dissection of the scleral tissues to access the tissues involved with ocular drainage. Deep sclerectomy is a form of this type of procedure in which a portion of intrascleral tissue is removed nearly to Descemet's membrane to allow significant aqueous flow from the anterior chamber to a bleb. Viscocanalostomy is another non-penetrating procedure, which increases the flow of aqueous humor form the anterior chamber into a surgically created intrascleral lake. Although non-penetrating procedures present fewer direct complications than traditional surgeries, most of the procedures still require the surgical dissection of ocular tissues and a high level of surgical skill.
- Various approaches and devices for glaucoma surgery involving the rerouting of aqueous humor have been described in the art. One approach involves the shunting of aqueous humor through a tube in the anterior chamber into a reservoir implanted on the surface of the eye. See Mendez U.S. Pat. No. 4,428,746, White U.S. Pat. No. 4,554,918, Molteno U.S. Pat. No. 4,750,901, Ahmed U.S. Pat. Nos. 5,071,408, 5,411,473, 5,616,118, 5,681,275, 5,785,674, 6,261,256, Baerveldt, et al. U.S. Pat. Nos. 5,178,604, 5,397,300, 5,558,629, 6,050,970, Speckman U.S. Pat. No. 5,338,291, Memmen U.S. Pat. No. 5,370,607, Jacob U.S. Pat. No. 5,882,327, Odrich U.S. Pat. No. 6,41,666. A similar approach is to shunt the aqueous humor through a tube placed in the anterior chamber into a bleb on the surface of the eye. See Worst U.S. Pat. No. 5,180,362, Suson U.S. Pat. No. 6,508,779, Wilcox WO 02/32343.
- Another approach described in the art is the shunting of aqueous humor from the anterior chamber to the tear film of the eye. See Ungerleider U.S. Pat. Nos. 4,936,825; 5,372,577; Wandel U.S. Pat. No. 5,807,302; Brown U.S. Pat. No. 6,595,945.
- Another approach described in the art is placing a shunt for aqueous humor through the trabecular meshwork to connect the anterior chamber and Schlemm's canal. See Lynch et al. U.S. Pat. No. 6,450,984, Hill U.S. Pat. No. 6,533,768, WO 01/78656, and Gharib et al. US 2002 0165478.
- The invention provides an apparatus for creating a tract within the scleral tissues of an eye comprising an elongated body portion shaped to create a tract which forms a path for flow of aqueous humor into an ocular vein. The elongated body portion has a proximal end and a distal end. The distal end may comprise a mechanically cutting tip or an energy source to ablate tissue. The distal end may be visible by medical imaging methods such as ultra sound, or optical coherence topography or visible under direct observation by an optical beacon at the tip. The apparatus may additionally accommodate a space-maintaining material for placement within the tract, such as hyaluronic acid or a cell proliferation inhibitor. These space-maintaining materials may also comprise a stent device made of hyaluronic acid, nickel, titanium alloy or other material.
- The invention also provides a method for creating a path for flow of aqueous humor of the eye into an ocular vein comprising;
- a. inserting an apparatus to form a tissue opening into an ocular vein on the anterior portion of the eye;
- b. directing the apparatus to create a tract from the vein to a source of aqueous humor,
- c. removing the apparatus;
- d. closing the tissue opening while retaining flow through the tract between the vein and the source.
- In another embodiment of the method the path is created by
- a. inserting the apparatus through a tissue opening in the eye into a source of aqueous humor;
- b. directing the apparatus to create a tract from the source into an ocular vein;
- c. removing the apparatus while retaining flow through the tract between the vein and the source; and
- d. optionally closing the tissue opening.
- The source of aqueous humor typically will comprise the anterior chamber, Schlemm's canal, the collector channel or a bleb.
-
FIG. 1 . Sectional view of the anterior portion of the human eye. -
FIG. 2 . Cross-sectional view of the drainage system in the human eye. -
FIG. 3 . Cross-sectional view of the drainage system in the human eye showing a microsurgical tool and tissue tract from an episcleral vein to the anterior chamber. -
FIG. 4 . Cross-sectional view of the drainage system in the human eye showing tissue tract from an episcleral vein to Schlemm's canal. -
FIG. 5 . Cross-sectional view of the of an embodiment of the invention comprising a microcannula assembly. -
FIG. 6 . View of an embodiment of a microcannula assembly incorporating fiber optic core for transmission of energy from a source. -
FIG. 7A . View of an embodiment of the invention comprising tube-stent devices. -
FIG. 7B . View of a stent device comprising alternating filament loops. -
FIG. 8A . Sectional view of the anterior portion of the human eye showing bypass implant comprising shape memory material incorporating a reduced diameter segment to maintain flow control at a minimum level. -
FIG. 8B . Sectional view of the anterior portion of the human eye showing laser energy being applied externally to increase the diameter of the shape memory bypass implant. -
FIG. 9 . Cross-sectional view of microcannula assembly incorporating a detachable tube stent as the distal sheath of the assembly. -
FIG. 10A . Sectional view of the anterior portion of the human eye showing detachable tube stent assembly creating tract from an episcleral vein to the anterior chamber. -
FIG. 10B . Sectional view of the anterior portion of the human eye showing tube stent in place after removal of the cannula assembly. - The present invention to provide minimally invasive microsurgical tools and methods, which enable surgical creation of a tissue tract within the tissues of the eye to directly connect a source of aqueous humor such as the anterior chamber, to an ocular vein, thereby forming a shunt or bypass for aqueous humor. The aqueous veins, into which aqueous humor normally drains, are good candidates for this procedure, however the invention is not limited to these specific vessels. Furthermore, the tissue tract from the vein may be connected to any source of aqueous humor, including the anterior chamber, an aqueous collector channel, Schlemm's canal, or a drainage bleb. Since the aqueous humor passes directly into the venous system, the normal drainage process for aqueous humor is restored. The tools and methods effectively bypass the small anatomical structures of the drainage system, such as the trabecular meshwork, Schlemm's canal and the collector channels, which have been identified with the mechanism of glaucoma. Furthermore, the invention describes devices and materials that can be implanted in the tract to maintain the tissue space and fluid flow post operatively.
- The invention comprises tools, materials and related methods to surgically create a bypass for aqueous humor.
FIG. 1 shows a sectional view of the anterior portion of the human eye for reference. The invention involves the steps of: firstly, identifying acandidate vein 4 on or within the eye of a living subject; secondly, inserting one or more tools into the eye to create a tissue tract in thesclera 3, that connects the vein to a source of aqueous humor such as the anterior chamber of theeye 1, or Schlemm'scanal 2; thirdly, optionally inserting an implant or material to maintain the tract opening and fluid flow, and; lastly, closing the surgical access site as required. The tools and materials comprise the apparatus to create a tissue tract within scleral tissues of the eye such that the tract acts as a fluid path for aqueous humor to the vein. - A magnified cross-sectional view of the drainage system of the human eye is shown in
FIG. 2 for reference. Anepiscleral vein 4 is identified suitable for creating the bypass. Candidate vessels can be found close to the surface of the eye, such as but not limited to, conjunctiva veins, anterior ciliary veins, and episcleral veins. Surface vessels can be directly visualized and accessed while subconjunctival vessels may require a small incision in the conjunctiva for access. Subsurface vessels such ascollector channels 5 andaqueous veins 6 can be identified by high-resolution medical imaging methods such as high frequency ultrasound (HFU) or optical coherence topography (OCT). The use of medical imaging is preferred in that veins which are in the most surgically desired location, can be selected. Vessels which are angled toward theanterior chamber 1, or Schlemm'scanal 2, and having appropriate dimensions and minimal tortuosity, can be identified as candidates for bypass. The use of an ultrasound or optical contrast agent, either delivered directly to the candidate vein or systemically to the subject, will facilitate vein identification. Doppler imaging can be used to assist identification of candidate blood vessels. Pressure changes applied to the anterior chamber will also facilitate vein identification and selection by distinguishing vessels with the most direct connection to the aqueous drainage system. In some situations the blood/aqueous interface can be seen in episcleral veins. Changes in pressure in the chamber will cause this interface to move forward and backward within the vein. Furthermore, pressure changes can result in a change of the apparent vein diameter, which can be directly observed. - Cross-sectional views of the drainage system of the human eye with a surgically created tissue tract are shown in
FIGS. 3 and 4 for reference. The use of HFU or OCT imaging is desired to determine the optimal placement of thetissue tract 7, from the candidate vein to theanterior chamber 1, or if desired, to a collector channel, Schlemm'scanal 2, or an existing bleb. When forming aconnection 9 of a vein to the anterior chamber, any region of the anterior chamber in proximity to the vein may be used including the area at the anterior segment angle and the corneal-scleral junction. The surgeon may use imaging techniques to pre-plan the route of the surgery and to verify locations, direction and placement of themicrosurgical tool 8, during the procedure. The method may comprise first access to avein 4, and then creating atract 7, toward and into a source of aqueous humor such as theanterior chamber 1. Alternatively, the method may comprise access from the anterior chamber first, and then through the subsurface tissues to a vein. The advantage of such a method is that the tissue penetration may be accomplished through clear cornea, starting 180° from the bypass point and transversing through the anterior chamber. The microsurgical tool is placed at the correct site for penetration of the tissues through to the candidate vein. Small, clear corneal incisions are self-sealing and therefore do not require closure mechanisms. If the initial penetration of the tool into the eye is elsewhere, then the entry inscision may need to be closed after removal of the tool. - The microsurgical tool may comprise an elongated tool, such as a microcannula, with a tip at one end which is directed into a vein. This may be a mechanically cutting tip such as a solid or hollow trocar-like member capable of creating a tunneled tract of controlled diameter through scleral tissues. In another embodiment, the tool may comprise a hollow tube with a sharpened distal edge used to core out a tissue tract. The removal of tissue may promote the subsequent stability of the tract and aid placement of an implant device into the channel. Referring to
FIG. 5 , the tool may comprise anouter sheath 11 and inner member, with the outer sheath disposed axially about the inner member. The inner member may comprise atrocar 10, solid rod, hollow rod or cylinder, needle, wire or optical fiber. The inner member may be designed to allow exchange during use to allow specific functions to be brought to the tip of the tool once it is located in tissue. The microcannula may be handled at its proximal end by a suitable accommodating mechanism such as luer fitting 12. - Referring to
FIG. 6 , an optical fiber inner member may be used to carry visible light to the tip of thefiber 13, which may be disposed to reside at the tip of the sheath and hence may be used for direct visualization of the location of the tool through scleral tissues. In the case of an opaque outer sheath material, a cutout section or window near the distal tip of the sheath may be provided to visualize the optical fiber tip. The optical fiber may be fabricated from glass, fused silica, or plastic that is optically transparent to the wavelength of light used for visualization. The described optical beacon can provide an adjunct method of tracking the creation of the tract, aiding HFU or OCT imaging. Alternately, the optical fiber may be used to carry energy for tissue ablation such as laser energy, in order to create the tract. The tip may also accommodate transmission of radio frequency or thermal energy to ablate or coagulate tissue. Thefiber optic line 14 is connected toenergy source 15. - The microsurgical tool is sized appropriate for access through small vessels and to create controlled diameter tissue tracts. Diameters from 50-500 microns are useful, and in particular diameters from 50-200 microns are preferred. Outer diameter of a sheath member may correspond to these ranges and may comprise a wall thickness between 10 and 100 microns. The microsurgical tool can comprise a flexible microcannula to allow the distal tip to be advanced within the vein toward a source of aqueous humor such as the anterior chamber. The microsurgical tool may be fabricated from structural materials such as metals including steel, titanium, and nickel-titanium alloys, structural polymers including polyimide, polyethylene, polyamide, polypropylene, polystyrene, polymethylmethacrylate, polytetrafluoroethylene, and polysulfone. Several tools with different material composition and design may be used sequentially in the surgical procedure. For example, one tool may be used to access the vessel and exchanged with a tool to create the scleral tissue tract. Alternatively, different types of inner members such as for cutting or light conduction may be used interchangeably within an outer sheath.
- The tool will accommodate features for orientation of the tract identified and controlled by the clinical practitioner. The use of medical imaging to coordinate or verify the position and orientation of the tract aids accuracy and precision of tract placement. Tools which are in the field of view of the imaging system allow for identification of the tool's position while minimizing the creation of artifacts into the image. Selection of tool material and/or the use of contrast markers can provide the desired imaging properties for the tools.
- The tract created may optionally be filled with a material to help maintain the patency and fluid flow of the tract. Such materials may comprise an anti-fibrotic material, anti-thrombotic agent, space maintaining material, tube-like stent or similar device to assure that the drainage tract remains patent. Anti-fibrotic materials such as hyaluronic acid and cellular proliferation inhibitors such as methotrexate, sirolimus, and paclitaxel, may be applied or released from a device within the tract. Anti-thrombotic agents such as heparin and tissue plasminogen activator may also be applied or released from a device within the tract. Such materials may be in the form of microspheres, microparticles, microfibers, open-or closed-cell matrices, foams, gels and tubes, which may be designed to change their configuration in-situ after implantation. The materials may comprise degradable materials such as hyaluronic acid, collagen , glycosoaminoglycans and degradable synthetic polymers. The materials may also comprise non-degradable materials with biocompatibility suitable for implant use including metals such as steel, titanium, and nickel-titanium alloys, and polymers such as polytetrafluoroethylene, polymethylmethacrylate, polyimide, polyethylene, polypropylene and polysulfone.
- A tubular stent-like device may be placed within the tract to enlarge the tract diameter or provide stabilization through mechanical means. Referring to
FIG. 7 a, there are examples shown of asimple tube 16 and afenestrated tube 17. The outer sheath of the microsurgical tool may comprise a tube-stent, and can be left behind after the tool core is removed. Referring toFIG. 9 , there is shown such a microcannula assembly comprising atrocar tip core 10, thedetachable stent 22, drivingcannula 23, and handle 24. The tube-stent may be pre-sized based on pre-surgical imaging or may be designed to be cut to size prior to or after implantation. The venous end of the tube-stent may be implanted to reside in the vein or further advanced to reside in a collector channel. The tube-stent may reside in the entire tissue tract between the vein and the aqueous humor source, or a portion of the tract. Several discrete tube-stents may also be used in stabilizing the tissue tract. - The diameter of the tube-stent may be designed to allow expansion in-situ, for example, by hydraulic pressure or thermal energy, or through the use of shape memory materials for construction of the tube-stent. Referring to
FIG. 8 b, alaser 20 is used to increase the diameter of ashape memory implant 21. For long-term stability, preferred are tube-stents designed to be conformable to the tissue tract and that do not create mechanical loads on the tissue other than for dilation of the tract. Mechanical features of the tube-stent such as tissue interfacing porosity may be incorporated to aid retention. Tube-like stents may be comprised of permanent or biodegradable materials. Suitable materials include metals such as steel, titanium and nickel titanium alloys, and biocompatible polymers such as hyaluronic acid, collagen, glycosoaminoglycans, polylactic acid, polyglycolic acid, polytetrafluoroethylene, polymethylmethacrylate, polyimide, polyethylene, polypropylene and polysulfone - Furthermore, the tube-stent device can also have a design to provide a controlled amount of flow restriction that would limit retrograde flow of blood. Devices with different flow resistance may be fabricated and chosen for optimization of aqueous flow by the practitioner. Referring to
FIG. 8 a, a shape memory stent incorporating areduced diameter segment 19 connects theanterior chamber 2 with anepiscleral vein 4 viaentry point 9. A valve may be incorporated into the tube stent to limit retrograde flow or to set a threshold pressure for flow. In another embodiment, the flow characteristics of the tube-stent may be varied after the procedure upon examination of the patient's IOP. Various energy sources such as laser light, RF or microwave may be directed at a portion of the implant to dilate or contract discrete segments to control flow. A photoreactive polymer or a pre-stressed polymer similar to heat shrink tubing may be employed to perform this function. - In a similar embodiment, the stent-like device may comprise a series of filaments or wires. Referring to
FIG. 7 b, the device may be formed as a woven tube or a series offilament loops 18. The filament loops may be attached to each other in an alternating, or “zigzag” pattern, or may be attached to a linear member along one axis. The loops may be disposed at an angle to the axis, and be sufficiently flexible to maintain the tract opening without creating undue stress upon the surrounding tissues. Such an embodiment allows for the stent device to conform to changes in diameter or direction of the tract. - The invention also provides methods to surgically create an aqueous bypass in the eye. The following methods are provided as explanatory and do not constitute the entire scope of methods which may be used in conjunction with the microsurgical tools described herein. Referring to
FIGS. 10 a and 10 b, in a first example, the surgeon will visually identify acandidate vein 4 on or about the surface of the eye. Using high resolution imaging techniques, a pathway from a target point along the axis of the vein to the desired endpoint, such as theanterior chamber 2, is mapped. A surgical tool comprising ahandle 24,tube stent sheath 22, and trocar is used. The trocar has a distal point configured to pierce the tissues. The tube-stent will be of correct length to connect the chamber and vein. The vein is cannulated with the tool at the target point, and the tool oriented in the angle and direction that was plotted from the imaging session. The tool is advanced along the pathway until the tip is seen penetrating the anterior chamber atentry point 9, preferably above the iris. The trocar inner member and the tool are removed, leaving the tube-stent 22 behind. Alternatively, a syringe containing an antifibrotic hydrogel can be attached to the proximal end of the sheath. The hydrogel is applied into the tract at the same time that the tool, including the sheath, is being withdrawn, to aid in maintaining the tract. The access site is then sealed by any requisite surgical method. - In another example, an episcleral vein is located by visualization through a surgical microscope. A target point is designated along the vein, at a distal point of sufficient diameter to accept the incoming microsurgical tool. An entry point is determined along the corneal limbus approximately 180° away from the candidate vein. A gonio lens is used to visually inspect the anterior angle at the bypass site to choose a target entry point to connect to the vein. The microsurgical tool in this instance comprises a fiber optic inner member with a trocar like distal tip and an outer member comprising a tube-stent of the correct length to connect the chamber and vein. The tool is advanced through the clear cornea at the entry point and advanced across the anterior chamber to the tissue entry point. The tool is then advanced through the tissues guided toward the candidate vein by visualization of the beacon tip of the tool. The tool is advanced until the distal tip enters the vein and then continued until a sufficient portion of the tube stent distal end is within the vessel to maintain flow. If sized correctly, the proximal end of the tube stent will now reside just within the anterior chamber. The tool is withdrawn, leaving the tube stent behind. The entry point may be surgically closed or allowed to self-seal.
- The procedure may also be performed on more than one venous site per eye as may be required to provide adequate drainage. In practice, the procedure may be performed on one site, and the patient's IOP monitored post-surgically. If more pressure reduction is required, then a subsequent procedure may be performed at another target site. Multiple drainage paths can thereby be created.
Claims (23)
1. An apparatus for creating a tract within the scleral tissues of an eye comprising:
an elongated body portion shaped to create said tract wherein said tract forms a path for flow of aqueous humor into an ocular vein.
2. The apparatus of claim 1 wherein said body portion comprises a proximal end and distal end.
3. The apparatus of claim 2 wherein said body portion has an outer diameter in the range of 50 to 500 microns.
4. The apparatus of claim 2 wherein said body portion comprises a flexible microcannula.
5. The apparatus of claim 2 wherein said distal end comprises a mechanical cutting tip.
6. The apparatus of claim 2 where in said distal end comprises an energy source to ablate tissue.
7. The apparatus of claim 6 wherein said energy comprises laser light, radio frequency energy, or thermal energy.
8. The apparatus of claim 2 where said distal end is visible by medical imaging.
9. The apparatus of claim 8 wherein medical imaging comprises ultrasound or optical coherence tomography.
10. The apparatus of claim 2 wherein said distal end comprises an optical beacon visible under direct observation through scleral tissues.
11. The apparatus of claim 2 wherein said body portion comprises an outer sheath and an inner member.
12. The apparatus of claim 11 wherein said inner member is removable during use from said outer sheath.
13. The apparatus of claim 1 which additionally comprises a space maintaining material placeable within said tract.
14. The apparatus of claim 13 wherein said space maintaining material comprises hyaluronic acid.
15. The apparatus of claim 13 wherein said space maintaining material comprises a cellular proliferation inhibitor.
16. The apparatus of claim 15 , wherein said cellular proliferation inhibitor comprises methotrexate, paclitaxel, or sirolimus.
17. The apparatus of claim 13 , wherein said space maintaining material comprises an anti-thrombotic agent.
18. The apparatus of claim 17 wherein said anti-thrombotic agent comprises heparin or tissue plasminogen activator.
19. The apparatus of claim 13 wherein said material comprises a stent device.
20. The apparatus of claim 19 wherein said device comprises hyaluronic acid.
21. The apparatus of claim 19 wherein said device comprises a nickel titanium alloy.
22. The apparatus of claim 19 wherein said device is changeable in situ from a first configuration to a second configuration.
23-30. (canceled)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/720,543 US20100191103A1 (en) | 2002-09-17 | 2010-03-09 | Apparatus and method for surgical bypass of aqueous humor |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41166802P | 2002-09-17 | 2002-09-17 | |
US10/528,276 US7699882B2 (en) | 2002-09-17 | 2003-09-17 | Apparatus and method for surgical bypass of aqueous humor |
PCT/US2003/029488 WO2004026347A2 (en) | 2002-09-17 | 2003-09-17 | Apparatus and method for surgical bypass of aqueous humor |
US12/720,543 US20100191103A1 (en) | 2002-09-17 | 2010-03-09 | Apparatus and method for surgical bypass of aqueous humor |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/528,276 Division US7699882B2 (en) | 2002-09-17 | 2003-09-17 | Apparatus and method for surgical bypass of aqueous humor |
PCT/US2003/029488 Division WO2004026347A2 (en) | 2002-09-17 | 2003-09-17 | Apparatus and method for surgical bypass of aqueous humor |
Publications (1)
Publication Number | Publication Date |
---|---|
US20100191103A1 true US20100191103A1 (en) | 2010-07-29 |
Family
ID=32030707
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/528,276 Expired - Fee Related US7699882B2 (en) | 2002-09-17 | 2003-09-17 | Apparatus and method for surgical bypass of aqueous humor |
US12/720,543 Abandoned US20100191103A1 (en) | 2002-09-17 | 2010-03-09 | Apparatus and method for surgical bypass of aqueous humor |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/528,276 Expired - Fee Related US7699882B2 (en) | 2002-09-17 | 2003-09-17 | Apparatus and method for surgical bypass of aqueous humor |
Country Status (5)
Country | Link |
---|---|
US (2) | US7699882B2 (en) |
EP (1) | EP1539066B1 (en) |
AU (1) | AU2003273339B2 (en) |
CA (1) | CA2499094C (en) |
WO (1) | WO2004026347A2 (en) |
Cited By (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100100104A1 (en) * | 2006-06-30 | 2010-04-22 | Aquesys, Inc. | Systems for reducing pressure in an organ |
US20130150770A1 (en) * | 2011-12-08 | 2013-06-13 | Aquesys, Inc. | Methods for placing a shunt into the intra-scleral space |
US20130296694A1 (en) * | 2012-05-04 | 2013-11-07 | The Cleveland Clinic Foundation | Surgical instruments for oct assisted procedures |
US8765210B2 (en) | 2011-12-08 | 2014-07-01 | Aquesys, Inc. | Systems and methods for making gelatin shunts |
US8801766B2 (en) | 2010-11-15 | 2014-08-12 | Aquesys, Inc. | Devices for deploying intraocular shunts |
US8828070B2 (en) | 2010-11-15 | 2014-09-09 | Aquesys, Inc. | Devices for deploying intraocular shunts |
US8852256B2 (en) | 2010-11-15 | 2014-10-07 | Aquesys, Inc. | Methods for intraocular shunt placement |
US8974511B2 (en) | 2010-11-15 | 2015-03-10 | Aquesys, Inc. | Methods for treating closed angle glaucoma |
US9017276B2 (en) | 2010-11-15 | 2015-04-28 | Aquesys, Inc. | Shunt placement through the sclera |
US9095411B2 (en) | 2010-11-15 | 2015-08-04 | Aquesys, Inc. | Devices for deploying intraocular shunts |
US9125723B2 (en) | 2013-02-19 | 2015-09-08 | Aquesys, Inc. | Adjustable glaucoma implant |
US9192516B2 (en) | 2010-11-15 | 2015-11-24 | Aquesys, Inc. | Intraocular shunt placement |
US9283116B2 (en) | 2010-11-15 | 2016-03-15 | Aquesys, Inc. | Intraocular shunt deployment device |
US9326891B2 (en) | 2010-11-15 | 2016-05-03 | Aquesys, Inc. | Methods for deploying intraocular shunts |
US9492320B2 (en) | 1999-04-26 | 2016-11-15 | Glaukos Corporation | Shunt device and method for treating ocular disorders |
US9554940B2 (en) | 2012-03-26 | 2017-01-31 | Glaukos Corporation | System and method for delivering multiple ocular implants |
US9572963B2 (en) | 2001-04-07 | 2017-02-21 | Glaukos Corporation | Ocular disorder treatment methods and systems |
US9585790B2 (en) | 2013-11-14 | 2017-03-07 | Aquesys, Inc. | Intraocular shunt inserter |
US9592151B2 (en) | 2013-03-15 | 2017-03-14 | Glaukos Corporation | Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye |
US9610195B2 (en) | 2013-02-27 | 2017-04-04 | Aquesys, Inc. | Intraocular shunt implantation methods and devices |
US9808373B2 (en) | 2013-06-28 | 2017-11-07 | Aquesys, Inc. | Intraocular shunt implantation |
US9962290B2 (en) | 2006-11-10 | 2018-05-08 | Glaukos Corporation | Uveoscleral shunt and methods for implanting same |
US9993368B2 (en) | 2000-04-14 | 2018-06-12 | Glaukos Corporation | System and method for treating an ocular disorder |
US10080682B2 (en) | 2011-12-08 | 2018-09-25 | Aquesys, Inc. | Intrascleral shunt placement |
US10085884B2 (en) | 2006-06-30 | 2018-10-02 | Aquesys, Inc. | Intraocular devices |
US10159600B2 (en) | 2013-02-19 | 2018-12-25 | Aquesys, Inc. | Adjustable intraocular flow regulation |
US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
US10245178B1 (en) | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
USD846738S1 (en) | 2017-10-27 | 2019-04-23 | Glaukos Corporation | Implant delivery apparatus |
US10285856B2 (en) | 2001-08-28 | 2019-05-14 | Glaukos Corporation | Implant delivery system and methods thereof for treating ocular disorders |
US10406029B2 (en) | 2001-04-07 | 2019-09-10 | Glaukos Corporation | Ocular system with anchoring implant and therapeutic agent |
US10463537B2 (en) | 2015-06-03 | 2019-11-05 | Aquesys Inc. | Ab externo intraocular shunt placement |
US10485701B2 (en) | 2002-04-08 | 2019-11-26 | Glaukos Corporation | Devices and methods for glaucoma treatment |
US10517759B2 (en) | 2013-03-15 | 2019-12-31 | Glaukos Corporation | Glaucoma stent and methods thereof for glaucoma treatment |
US10667947B2 (en) | 2016-06-02 | 2020-06-02 | Aquesys, Inc. | Intraocular drug delivery |
WO2020121061A3 (en) * | 2018-12-13 | 2020-07-30 | Ioptima Ltd. | Methods and systems for laser assisted technology for minimally-invasive ab-interno glaucoma surgery |
US10842671B2 (en) | 2010-11-15 | 2020-11-24 | Aquesys, Inc. | Intraocular shunt placement in the suprachoroidal space |
US10952898B2 (en) | 2018-03-09 | 2021-03-23 | Aquesys, Inc. | Intraocular shunt inserter |
US10959941B2 (en) | 2014-05-29 | 2021-03-30 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
US11116625B2 (en) | 2017-09-28 | 2021-09-14 | Glaukos Corporation | Apparatus and method for controlling placement of intraocular implants |
US11135089B2 (en) | 2018-03-09 | 2021-10-05 | Aquesys, Inc. | Intraocular shunt inserter |
US11246753B2 (en) | 2017-11-08 | 2022-02-15 | Aquesys, Inc. | Manually adjustable intraocular flow regulation |
US11318043B2 (en) | 2016-04-20 | 2022-05-03 | Dose Medical Corporation | Bioresorbable ocular drug delivery device |
US11376040B2 (en) | 2017-10-06 | 2022-07-05 | Glaukos Corporation | Systems and methods for delivering multiple ocular implants |
US11564833B2 (en) | 2015-09-25 | 2023-01-31 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
US11925578B2 (en) | 2015-09-02 | 2024-03-12 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
Families Citing this family (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7699882B2 (en) * | 2002-09-17 | 2010-04-20 | Iscience Interventional Corporation | Apparatus and method for surgical bypass of aqueous humor |
US20040225250A1 (en) | 2003-05-05 | 2004-11-11 | Michael Yablonski | Internal shunt and method for treating glaucoma |
US7291125B2 (en) | 2003-11-14 | 2007-11-06 | Transcend Medical, Inc. | Ocular pressure regulation |
MXPA06012460A (en) * | 2004-04-29 | 2007-07-13 | Iscience Surgical Corp | Apparatus and method for surgical enhancement of aqueous humor drainage. |
US20100173866A1 (en) * | 2004-04-29 | 2010-07-08 | Iscience Interventional Corporation | Apparatus and method for ocular treatment |
SE0401182D0 (en) | 2004-05-05 | 2004-05-05 | Q Med Ab | Novel use of a viscoelastic composition |
US8920391B2 (en) * | 2004-06-18 | 2014-12-30 | Sunless, Inc. | Container for system for spray coating human subject |
US20050279865A1 (en) * | 2004-06-18 | 2005-12-22 | Innovative Developments, Llc | Fluid spraying system |
US20100129557A1 (en) * | 2004-06-18 | 2010-05-27 | Mt Industries, Inc. | Spray coating at least one portion of a subject |
US20070197982A1 (en) * | 2006-01-05 | 2007-08-23 | Scott Thomason | Automatic body spray system |
EP3632385A1 (en) | 2006-01-17 | 2020-04-08 | Novartis AG | Glaucoma treatment device |
WO2007084582A2 (en) | 2006-01-17 | 2007-07-26 | Forsight Labs, Llc | Drug delivery treatment device |
US7909789B2 (en) | 2006-06-26 | 2011-03-22 | Sight Sciences, Inc. | Intraocular implants and methods and kits therefor |
US20080215078A1 (en) * | 2007-01-31 | 2008-09-04 | Bennett Michael D | Surgical blade and trocar system |
EP2173289A4 (en) * | 2007-07-17 | 2010-11-24 | Transcend Medical Inc | Ocular implant with hydrogel expansion capabilities |
US7740604B2 (en) | 2007-09-24 | 2010-06-22 | Ivantis, Inc. | Ocular implants for placement in schlemm's canal |
US8425449B2 (en) | 2009-07-09 | 2013-04-23 | Ivantis, Inc. | Ocular implants and methods for delivering ocular implants into the eye |
US20170360609A9 (en) | 2007-09-24 | 2017-12-21 | Ivantis, Inc. | Methods and devices for increasing aqueous humor outflow |
US20090082862A1 (en) | 2007-09-24 | 2009-03-26 | Schieber Andrew T | Ocular Implant Architectures |
US8734377B2 (en) | 2007-09-24 | 2014-05-27 | Ivantis, Inc. | Ocular implants with asymmetric flexibility |
US8808222B2 (en) | 2007-11-20 | 2014-08-19 | Ivantis, Inc. | Methods and apparatus for delivering ocular implants into the eye |
US8512404B2 (en) | 2007-11-20 | 2013-08-20 | Ivantis, Inc. | Ocular implant delivery system and method |
CA2717441A1 (en) | 2008-03-05 | 2009-09-11 | Ivantis, Inc. | Methods and apparatus for treating glaucoma |
ES2640867T3 (en) | 2008-06-25 | 2017-11-07 | Novartis Ag | Eye implant with ability to change shape |
US8343214B2 (en) * | 2008-10-20 | 2013-01-01 | Cateract Innovations LLC | Apparatus for the treatment of cataract |
US8353856B2 (en) | 2008-11-05 | 2013-01-15 | Abbott Medical Optics Inc. | Glaucoma drainage shunts and methods of use |
CA2745884C (en) | 2008-12-05 | 2017-08-01 | Ivantis, Inc. | Cannula for ocular implant delivery system |
CH700161A2 (en) * | 2008-12-22 | 2010-06-30 | Grieshaber Ophthalmic Res Foun | IMPLANT FOR INTRODUCING into Schlemm's canal AN EYE. |
US8425473B2 (en) | 2009-01-23 | 2013-04-23 | Iscience Interventional Corporation | Subretinal access device |
US20100191177A1 (en) * | 2009-01-23 | 2010-07-29 | Iscience Interventional Corporation | Device for aspirating fluids |
JP5524983B2 (en) | 2009-01-28 | 2014-06-18 | トランセンド・メディカル・インコーポレイテッド | Implant system |
US8657883B2 (en) | 2009-03-23 | 2014-02-25 | Ut-Battelle, Llc | Remote actuated valve implant |
US8337393B2 (en) | 2009-04-03 | 2012-12-25 | Transcend Medical, Inc. | Ocular implant delivery systems and methods |
AU2010271274B2 (en) | 2009-07-09 | 2015-05-21 | Alcon Inc. | Single operator device for delivering an ocular implant |
US8951221B2 (en) * | 2009-08-20 | 2015-02-10 | Grieshaber Ophthalmic Research Foundation | Method and device for the treatment of glaucoma |
CA2778452A1 (en) | 2009-10-23 | 2011-04-28 | Ivantis, Inc. | Ocular implant system and method |
US8845572B2 (en) | 2009-11-13 | 2014-09-30 | Grieshaber Ophthalmic Research Foundation | Method and device for the treatment of glaucoma |
US8529492B2 (en) | 2009-12-23 | 2013-09-10 | Trascend Medical, Inc. | Drug delivery devices and methods |
WO2011097408A1 (en) | 2010-02-05 | 2011-08-11 | Sight Sciences, Inc | Intraocular implants and related kits and methods |
US20110213317A1 (en) * | 2010-03-01 | 2011-09-01 | Chen David E-Bin | Cannula for intraocular surgery |
CN103002842A (en) * | 2010-05-27 | 2013-03-27 | I科学干预公司 | Device for placing circumferential implant in schlemm's canal |
US8545430B2 (en) | 2010-06-09 | 2013-10-01 | Transcend Medical, Inc. | Expandable ocular devices |
WO2011163505A1 (en) | 2010-06-23 | 2011-12-29 | Ivantis, Inc. | Ocular implants deployed in schlemm's canal of the eye |
CA2827306C (en) | 2011-02-23 | 2018-03-27 | Grieshaber Ophthalmic Research Foundation | Implant for the treatment of glaucoma |
US8657776B2 (en) | 2011-06-14 | 2014-02-25 | Ivantis, Inc. | Ocular implants for delivery into the eye |
CN102824238B (en) * | 2011-06-16 | 2014-07-09 | 王宁利 | Schlemm tube expansion bracket and combined body thereof |
US9381112B1 (en) | 2011-10-06 | 2016-07-05 | William Eric Sponsell | Bleb drainage device, ophthalmological product and methods |
US8663150B2 (en) | 2011-12-19 | 2014-03-04 | Ivantis, Inc. | Delivering ocular implants into the eye |
US8632489B1 (en) | 2011-12-22 | 2014-01-21 | A. Mateen Ahmed | Implantable medical assembly and methods |
EP2844200B1 (en) | 2012-03-20 | 2020-11-25 | Sight Sciences, Inc | Ocular delivery systems |
US9358156B2 (en) | 2012-04-18 | 2016-06-07 | Invantis, Inc. | Ocular implants for delivery into an anterior chamber of the eye |
US10085633B2 (en) | 2012-04-19 | 2018-10-02 | Novartis Ag | Direct visualization system for glaucoma treatment |
US9241832B2 (en) | 2012-04-24 | 2016-01-26 | Transcend Medical, Inc. | Delivery system for ocular implant |
RU2650203C2 (en) | 2012-09-17 | 2018-04-11 | Новартис Аг | Expanding ocular implant devices |
US9763829B2 (en) | 2012-11-14 | 2017-09-19 | Novartis Ag | Flow promoting ocular implant |
US10617558B2 (en) | 2012-11-28 | 2020-04-14 | Ivantis, Inc. | Apparatus for delivering ocular implants into an anterior chamber of the eye |
US9987163B2 (en) | 2013-04-16 | 2018-06-05 | Novartis Ag | Device for dispensing intraocular substances |
US10010447B2 (en) | 2013-12-18 | 2018-07-03 | Novartis Ag | Systems and methods for subretinal delivery of therapeutic agents |
US9205181B2 (en) | 2014-01-09 | 2015-12-08 | Rainbow Medical, Ltd. | Injectable hydrogel implant for treating glaucoma |
WO2016011056A1 (en) | 2014-07-14 | 2016-01-21 | Ivantis, Inc. | Ocular implant delivery system and method |
US10299958B2 (en) | 2015-03-31 | 2019-05-28 | Sight Sciences, Inc. | Ocular delivery systems and methods |
CN108135470B (en) | 2015-08-14 | 2021-03-09 | 伊万提斯公司 | Ocular implant with pressure sensor and delivery system |
WO2017106517A1 (en) | 2015-12-15 | 2017-06-22 | Ivantis, Inc. | Ocular implant and delivery system |
US20190117459A1 (en) | 2017-06-16 | 2019-04-25 | Michael S. Berlin | Methods and Systems for OCT Guided Glaucoma Surgery |
US20180360655A1 (en) | 2017-06-16 | 2018-12-20 | Michael S. Berlin | Methods and systems for oct guided glaucoma surgery |
US11166849B2 (en) * | 2017-07-20 | 2021-11-09 | Shifamed Holdings, Llc | Adjustable flow glaucoma shunts and methods for making and using same |
EP4218692A3 (en) * | 2017-07-20 | 2023-09-06 | Shifamed Holdings, LLC | Adjustable flow glaucoma shunts and methods for making and using same |
WO2019032848A1 (en) * | 2017-08-11 | 2019-02-14 | University Of Florida Research Foundation, Inc. | Enhanced drainage of failed glaucoma drainage device (gdd) |
US11576816B2 (en) * | 2017-10-18 | 2023-02-14 | Jesus Moreno | Opthalmic microsurgical instrument |
US10987247B2 (en) | 2017-10-18 | 2021-04-27 | Jesus Moreno | Opthalmic microsurgical instrument |
US20230181363A1 (en) * | 2018-09-27 | 2023-06-15 | Nova Eye, Inc. | Opthalmic microsurgical instrument |
US20220087865A1 (en) * | 2019-01-18 | 2022-03-24 | Shifamed Holdings, Llc | Adjustable flow glaucoma shunts and methods for making and using same |
US11259961B2 (en) | 2019-07-22 | 2022-03-01 | Iantrek, Inc. | Methods and devices for increasing aqueous drainage of the eye |
US11504270B1 (en) | 2019-09-27 | 2022-11-22 | Sight Sciences, Inc. | Ocular delivery systems and methods |
WO2021072315A1 (en) | 2019-10-10 | 2021-04-15 | Shifamed Holdings, Llc | Adjustable flow glaucoma shunts and associated systems and methods |
US11529258B2 (en) | 2020-01-23 | 2022-12-20 | Shifamed Holdings, Llc | Adjustable flow glaucoma shunts and associated systems and methods |
AU2021219845A1 (en) | 2020-02-14 | 2022-09-01 | Shifamed Holdings, Llc | Shunting systems with rotation-based flow control assemblies, and associated systems and methods |
EP4106695A4 (en) | 2020-02-18 | 2024-03-20 | Shifamed Holdings Llc | Adjustable flow glaucoma shunts having non-linearly arranged flow control elements, and associated systems and methods |
US11766355B2 (en) | 2020-03-19 | 2023-09-26 | Shifamed Holdings, Llc | Intraocular shunts with low-profile actuation elements and associated systems and methods |
CN115867237A (en) | 2020-04-16 | 2023-03-28 | 施菲姆德控股有限责任公司 | Adjustable glaucoma treatment devices and related systems and methods |
JP2024503989A (en) | 2021-01-11 | 2024-01-30 | アルコン インコーポレイティド | Systems and methods for viscoelastic delivery |
EP4281144A1 (en) | 2021-01-22 | 2023-11-29 | Shifamed Holdings, LLC | Adjustable shunting systems with plate assemblies, and associated systems and methods |
Citations (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3659607A (en) * | 1968-09-16 | 1972-05-02 | Surgical Design Corp | Method for performing surgical procedures on the eye |
US4515583A (en) * | 1983-10-17 | 1985-05-07 | Coopervision, Inc. | Operative elliptical probe for ultrasonic surgical instrument and method of its use |
US4521210A (en) * | 1982-12-27 | 1985-06-04 | Wong Vernon G | Eye implant for relieving glaucoma, and device and method for use therewith |
US4567882A (en) * | 1982-12-06 | 1986-02-04 | Vanderbilt University | Method for locating the illuminated tip of an endotracheal tube |
US4607622A (en) * | 1985-04-11 | 1986-08-26 | Charles D. Fritch | Fiber optic ocular endoscope |
US4735606A (en) * | 1982-10-12 | 1988-04-05 | Sherwood Medical Company | Chest drainage apparatus |
US4744362A (en) * | 1985-06-27 | 1988-05-17 | Gruendler Patrik | Device for transplanting the cornea of the human eye |
US4968296A (en) * | 1989-12-20 | 1990-11-06 | Robert Ritch | Transscleral drainage implant device for the treatment of glaucoma |
US5037384A (en) * | 1988-01-12 | 1991-08-06 | Cornell Research Foundation, Inc. | Method and apparatus for the treatment of complicated retinal detachments |
US5059186A (en) * | 1988-03-07 | 1991-10-22 | Vitaphore Corporation | Percutaneous access device |
US5164188A (en) * | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
US5181922A (en) * | 1991-07-29 | 1993-01-26 | Escalon Ophthalmics, Inc. | Method for indenting the ocular coats of an eye |
US5273530A (en) * | 1990-11-14 | 1993-12-28 | The University Of Rochester | Intraretinal delivery and withdrawal instruments |
US5286261A (en) * | 1990-08-30 | 1994-02-15 | Jaime Roizenblatt | Inflatable balloon for treatment of rental detachments |
US5364374A (en) * | 1992-04-10 | 1994-11-15 | State Of Oregon | Microneedle for injection of ocular blood vessels |
US5370640A (en) * | 1993-07-01 | 1994-12-06 | Kolff; Jack | Intracorporeal catheter placement apparatus and method |
US5443505A (en) * | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
US5486165A (en) * | 1992-01-10 | 1996-01-23 | Stegmann; Robert | Method and appliance for maintaining the natural intraocular pressure |
US5487725A (en) * | 1994-05-12 | 1996-01-30 | Syntec, Inc. | Pneumatic vitrectomy for retinal attachment |
US5545153A (en) * | 1994-08-15 | 1996-08-13 | A.V.I. - Advanced Visual Instruments, Inc. | Adjustable miniature panoramic illumination and infusion system for retinal surgery |
US5547473A (en) * | 1994-05-12 | 1996-08-20 | Syntec, Inc. | Pneumatic vitrectomy for retinal attachment |
US5660851A (en) * | 1989-12-26 | 1997-08-26 | Yissum Research Development Company Of The Hebrew Univ. Of Jerusalem | Ocular inserts |
US5817075A (en) * | 1989-08-14 | 1998-10-06 | Photogenesis, Inc. | Method for preparation and transplantation of planar implants and surgical instrument therefor |
US5860923A (en) * | 1995-01-30 | 1999-01-19 | Cardiovascular Concepts, Inc. | Lesion measurement catheter and method |
US5929111A (en) * | 1996-12-18 | 1999-07-27 | Alcon Laboratories, Inc. | A-seco steroids effective at treating ophthalmic pathological neovascularization and controlling intraocular pressure |
US5952378A (en) * | 1994-08-24 | 1999-09-14 | Pharmacia & Upjohn Ab | Methods and means for drug administration |
US5962027A (en) * | 1989-08-14 | 1999-10-05 | Photogenesis, Inc. | Retinal cell transplant |
US5972416A (en) * | 1993-11-10 | 1999-10-26 | Mentor Corporation | Bipolar electrosurgical instrument and method for making the instrument |
US6024719A (en) * | 1998-07-06 | 2000-02-15 | Morris; Robert E | Method and apparatus for performing surgery inside the human retina using fluidic internal limiting membrane (ILM) seperation (FILMS) |
US6045791A (en) * | 1992-03-06 | 2000-04-04 | Photogenesis, Inc. | Retinal pigment epithelium transplantation |
US6102895A (en) * | 1997-09-30 | 2000-08-15 | Cortella; Julian M. | Digital fluid delivery and aspiration apparatus with mechanical de-amplifier |
US6112747A (en) * | 1998-11-06 | 2000-09-05 | Jones; Jesse M. | Method of sterilizing females |
US6142990A (en) * | 1997-02-15 | 2000-11-07 | Heidelberg Engineering Optische Messsysteme Gmbh | Medical apparatus, especially for reducing intraocular pressure |
US6149931A (en) * | 1997-10-27 | 2000-11-21 | The Regents Of The University Of California | Methods and pharmaceutical compositions for the closure of retinal breaks |
US6156042A (en) * | 1997-11-17 | 2000-12-05 | Aramant; Robert B. | Retinal tissue implantation instrument |
US20010011165A1 (en) * | 1993-05-12 | 2001-08-02 | Engelson Erik T. | Lubricious catheters |
US20010044595A1 (en) * | 2000-05-02 | 2001-11-22 | Wilson-Cook Medical, Inc. | Introducer apparatus with eversible sleeve |
US20010053873A1 (en) * | 1999-11-24 | 2001-12-20 | Hansgeorg Schaaf | Device for improving drainage of the aqueous humor within the eye of a living being |
US20020026176A1 (en) * | 2000-08-30 | 2002-02-28 | Varner Signe Erickson | Devices for intraocular drug delivery |
US6378526B1 (en) * | 1998-08-03 | 2002-04-30 | Insite Vision, Incorporated | Methods of ophthalmic administration |
US6402734B1 (en) * | 1998-07-02 | 2002-06-11 | Jeffrey N. Weiss | Apparatus and method for cannulating retinal blood vessels |
US6413245B1 (en) * | 1999-10-21 | 2002-07-02 | Alcon Universal Ltd. | Sub-tenon drug delivery |
US6468283B1 (en) * | 1995-05-14 | 2002-10-22 | Optonol, Ltd. | Method of regulating pressure with an intraocular implant |
US20020169468A1 (en) * | 2001-01-09 | 2002-11-14 | J.David Brown | Glaucoma treatment device and method |
US20030014036A1 (en) * | 2001-06-12 | 2003-01-16 | Varner Signe Erickson | Reservoir device for intraocular drug delivery |
US6524275B1 (en) * | 1999-04-26 | 2003-02-25 | Gmp Vision Solutions, Inc. | Inflatable device and method for treating glaucoma |
US6544249B1 (en) * | 1996-11-29 | 2003-04-08 | The Lions Eye Institute Of Western Australia Incorporated | Biological microfistula tube and implantation method and apparatus |
US6668190B2 (en) * | 2000-06-16 | 2003-12-23 | Wayne State University | Method and apparatus for activating molecules to stimulate neurological tissue |
US20040015140A1 (en) * | 2002-07-19 | 2004-01-22 | Shields Milton B. | Uveoscleral drainage device |
US6692759B1 (en) * | 2000-06-28 | 2004-02-17 | The Regents Of The University Of California | Methods for preparing and using implantable substance delivery devices |
US20040039401A1 (en) * | 2000-03-31 | 2004-02-26 | Chow Alan Y. | Implant instrument |
US20040039253A1 (en) * | 2002-08-20 | 2004-02-26 | Peyman Gholam A. | Treatment of retinal detachment |
US20040050392A1 (en) * | 2001-08-28 | 2004-03-18 | Hosheng Tu | Glaucoma stent for treating glaucoma and methods of use |
US6726676B2 (en) * | 2000-01-05 | 2004-04-27 | Grieshaber & Co. Ag Schaffhausen | Method of and device for improving the flow of aqueous humor within the eye |
US6766817B2 (en) * | 2001-07-25 | 2004-07-27 | Tubarc Technologies, Llc | Fluid conduction utilizing a reversible unsaturated siphon with tubarc porosity action |
US20040199130A1 (en) * | 2003-04-03 | 2004-10-07 | Chornenky Victor I. | Apparatus and method for treatment of macular degeneration |
US20040249404A1 (en) * | 2001-11-22 | 2004-12-09 | Haefliger Eduard Anton | Device and method for the performance of ophthalmological operations |
US20040254520A1 (en) * | 2001-04-07 | 2004-12-16 | Eric Porteous | Coil implant for glaucoma treatment |
US6875165B2 (en) * | 2001-02-22 | 2005-04-05 | Retinalabs, Inc. | Method of radiation delivery to the eye |
US6908476B2 (en) * | 2001-12-21 | 2005-06-21 | Alcon Grieshaber Ag | Micro surgical cutting instrument configured as scissors |
US20050171507A1 (en) * | 2004-01-23 | 2005-08-04 | Christian Jeffrey J. | Composite ophthalmic microcannula |
US20060084943A1 (en) * | 2000-04-05 | 2006-04-20 | Biocardia, Inc. | Implant delivery catheter system and methods for its use |
US20060110428A1 (en) * | 2004-07-02 | 2006-05-25 | Eugene Dejuan | Methods and devices for the treatment of ocular conditions |
US20060200097A1 (en) * | 2003-01-24 | 2006-09-07 | Doheny Retina Institute | Reservoirs with subretinal cannula for subretinal drug delivery |
US7122042B2 (en) * | 2001-03-15 | 2006-10-17 | Lorusso Frank J | Apparatuses and methods for transcleral cautery and subretinal drainage |
US7141048B1 (en) * | 2002-10-17 | 2006-11-28 | Alcon, Inc. | Vitreoretinal instrument |
US7189245B2 (en) * | 2002-02-14 | 2007-03-13 | Photogenesis, Inc. | Subretinal implantation device and surgical cannulas for use therewith |
US20070083221A1 (en) * | 2005-10-12 | 2007-04-12 | Sismed, Llc | Precision trephine |
US7217263B2 (en) * | 2000-01-03 | 2007-05-15 | The Johns Hopkins University | Device and method for manual retinal vein catheterization |
US7220238B2 (en) * | 1999-04-26 | 2007-05-22 | Gmp Vision Solutions, Inc. | Shunt device and method for treating glaucoma |
US7247702B2 (en) * | 2002-02-28 | 2007-07-24 | The Penn State Research Foundation | Periocular drug delivery for diabetic retinopathy |
US7273445B2 (en) * | 2003-04-30 | 2007-09-25 | Board Of Trustees Of The University Of Illinois | Intraocular brachytherapy device and method |
US20070239066A1 (en) * | 2006-01-25 | 2007-10-11 | Laham Roger J | Devices and methods for tissue transplant and regeneration |
US20070244520A1 (en) * | 2004-04-19 | 2007-10-18 | Searete Llc | Lumen-traveling biological interface device and method of use |
US7285107B1 (en) * | 2002-10-17 | 2007-10-23 | Alcon, Inc. | Vitreoretinal instrument |
US7285255B2 (en) * | 2002-12-10 | 2007-10-23 | Ecolab Inc. | Deodorizing and sanitizing employing a wicking device |
US7699882B2 (en) * | 2002-09-17 | 2010-04-20 | Iscience Interventional Corporation | Apparatus and method for surgical bypass of aqueous humor |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4428746A (en) * | 1981-07-29 | 1984-01-31 | Antonio Mendez | Glaucoma treatment device |
US4554918A (en) * | 1982-07-28 | 1985-11-26 | White Thomas C | Ocular pressure relief device |
NZ215409A (en) * | 1986-03-07 | 1989-02-24 | Anthony Christopher Be Molteno | Implant for drainage of aqueous humour in glaucoma |
US4862891A (en) * | 1988-03-14 | 1989-09-05 | Canyon Medical Products | Device for sequential percutaneous dilation |
US4936825A (en) * | 1988-04-11 | 1990-06-26 | Ungerleider Bruce A | Method for reducing intraocular pressure caused by glaucoma |
US5785674A (en) * | 1988-10-07 | 1998-07-28 | Mateen; Ahmed Abdul | Device and method for treating glaucoma |
US5681275A (en) * | 1988-10-07 | 1997-10-28 | Ahmed; Abdul Mateen | Ophthalmological device with adaptable multiple distribution plates |
US5071408A (en) * | 1988-10-07 | 1991-12-10 | Ahmed Abdul Mateen | Medical valve |
US5616118A (en) * | 1988-10-07 | 1997-04-01 | Ahmed; Abdul M. | Uniquely shaped ophthalmological device |
US5180362A (en) * | 1990-04-03 | 1993-01-19 | Worst J G F | Gonio seton |
US5178604A (en) * | 1990-05-31 | 1993-01-12 | Iovision, Inc. | Glaucoma implant |
US5397300A (en) * | 1990-05-31 | 1995-03-14 | Iovision, Inc. | Glaucoma implant |
US5300020A (en) * | 1991-05-31 | 1994-04-05 | Medflex Corporation | Surgically implantable device for glaucoma relief |
US5370607A (en) | 1992-10-28 | 1994-12-06 | Annuit Coeptis, Inc. | Glaucoma implant device and method for implanting same |
US5338291A (en) * | 1993-02-03 | 1994-08-16 | Pudenz-Schulte Medical Research Corporation | Glaucoma shunt and method for draining aqueous humor |
US5390607A (en) * | 1994-01-03 | 1995-02-21 | Johnstown America Corporation | Non-metallic polymer longitudinal hood collar |
US5891084A (en) * | 1994-12-27 | 1999-04-06 | Lee; Vincent W. | Multiple chamber catheter delivery system |
US5626558A (en) * | 1995-05-05 | 1997-05-06 | Suson; John | Adjustable flow rate glaucoma shunt and method of using same |
US5807302A (en) * | 1996-04-01 | 1998-09-15 | Wandel; Thaddeus | Treatment of glaucoma |
US6261256B1 (en) * | 1996-12-20 | 2001-07-17 | Abdul Mateen Ahmed | Pocket medical valve & method |
US5882327A (en) * | 1997-04-17 | 1999-03-16 | Jacob; Jean T. | Long-term glaucoma drainage implant |
US6050970A (en) * | 1997-05-08 | 2000-04-18 | Pharmacia & Upjohn Company | Method and apparatus for inserting a glaucoma implant in an anterior and posterior segment of the eye |
EP0898947A3 (en) * | 1997-08-15 | 1999-09-08 | GRIESHABER & CO. AG SCHAFFHAUSEN | Method and apparatus to improve the outflow of the aqueous humor of an eye |
US6056700A (en) * | 1998-10-13 | 2000-05-02 | Emx, Inc. | Biopsy marker assembly and method of use |
US6471666B1 (en) * | 2000-02-24 | 2002-10-29 | Steven A. Odrich | Injectable glaucoma device |
US6533768B1 (en) * | 2000-04-14 | 2003-03-18 | The Regents Of The University Of California | Device for glaucoma treatment and methods thereof |
US6699211B2 (en) * | 2000-08-22 | 2004-03-02 | James A. Savage | Method and apparatus for treatment of glaucoma |
WO2002036052A1 (en) * | 2000-11-01 | 2002-05-10 | Glaukos Corporation | Glaucoma treatment device |
US6666841B2 (en) * | 2001-05-02 | 2003-12-23 | Glaukos Corporation | Bifurcatable trabecular shunt for glaucoma treatment |
-
2003
- 2003-09-17 US US10/528,276 patent/US7699882B2/en not_active Expired - Fee Related
- 2003-09-17 EP EP03755839A patent/EP1539066B1/en not_active Expired - Lifetime
- 2003-09-17 CA CA2499094A patent/CA2499094C/en not_active Expired - Fee Related
- 2003-09-17 WO PCT/US2003/029488 patent/WO2004026347A2/en active Application Filing
- 2003-09-17 AU AU2003273339A patent/AU2003273339B2/en not_active Ceased
-
2010
- 2010-03-09 US US12/720,543 patent/US20100191103A1/en not_active Abandoned
Patent Citations (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3659607A (en) * | 1968-09-16 | 1972-05-02 | Surgical Design Corp | Method for performing surgical procedures on the eye |
US4735606A (en) * | 1982-10-12 | 1988-04-05 | Sherwood Medical Company | Chest drainage apparatus |
US4567882A (en) * | 1982-12-06 | 1986-02-04 | Vanderbilt University | Method for locating the illuminated tip of an endotracheal tube |
US4521210A (en) * | 1982-12-27 | 1985-06-04 | Wong Vernon G | Eye implant for relieving glaucoma, and device and method for use therewith |
US4515583A (en) * | 1983-10-17 | 1985-05-07 | Coopervision, Inc. | Operative elliptical probe for ultrasonic surgical instrument and method of its use |
US4607622A (en) * | 1985-04-11 | 1986-08-26 | Charles D. Fritch | Fiber optic ocular endoscope |
US4744362A (en) * | 1985-06-27 | 1988-05-17 | Gruendler Patrik | Device for transplanting the cornea of the human eye |
US5037384A (en) * | 1988-01-12 | 1991-08-06 | Cornell Research Foundation, Inc. | Method and apparatus for the treatment of complicated retinal detachments |
US5037384B2 (en) * | 1988-01-12 | 1995-12-26 | Cornell Res Foundation Inc | Method and apparatus for the treatment of complicated retinal detachments |
US5037384B1 (en) * | 1988-01-12 | 1994-08-16 | Cornell Res Foundation Inc | Method and apparatus for the treatment of complicated retinal detachments |
US5059186A (en) * | 1988-03-07 | 1991-10-22 | Vitaphore Corporation | Percutaneous access device |
US5962027A (en) * | 1989-08-14 | 1999-10-05 | Photogenesis, Inc. | Retinal cell transplant |
US20060039993A1 (en) * | 1989-08-14 | 2006-02-23 | Hughes Stephen E | Retinal cell grafts and instrument for implanting |
US6579256B2 (en) * | 1989-08-14 | 2003-06-17 | Photogenesis, Inc. | Instrument for subretinal implantation |
US5817075A (en) * | 1989-08-14 | 1998-10-06 | Photogenesis, Inc. | Method for preparation and transplantation of planar implants and surgical instrument therefor |
US5164188A (en) * | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
US4968296A (en) * | 1989-12-20 | 1990-11-06 | Robert Ritch | Transscleral drainage implant device for the treatment of glaucoma |
US5660851A (en) * | 1989-12-26 | 1997-08-26 | Yissum Research Development Company Of The Hebrew Univ. Of Jerusalem | Ocular inserts |
US5286261A (en) * | 1990-08-30 | 1994-02-15 | Jaime Roizenblatt | Inflatable balloon for treatment of rental detachments |
US5409457A (en) * | 1990-11-14 | 1995-04-25 | The University Of Rochester | Intraretinal delivery and withdrawal instruments |
US5273530A (en) * | 1990-11-14 | 1993-12-28 | The University Of Rochester | Intraretinal delivery and withdrawal instruments |
US5181922A (en) * | 1991-07-29 | 1993-01-26 | Escalon Ophthalmics, Inc. | Method for indenting the ocular coats of an eye |
US5486165A (en) * | 1992-01-10 | 1996-01-23 | Stegmann; Robert | Method and appliance for maintaining the natural intraocular pressure |
US6045791A (en) * | 1992-03-06 | 2000-04-04 | Photogenesis, Inc. | Retinal pigment epithelium transplantation |
US5364374A (en) * | 1992-04-10 | 1994-11-15 | State Of Oregon | Microneedle for injection of ocular blood vessels |
US20010011165A1 (en) * | 1993-05-12 | 2001-08-02 | Engelson Erik T. | Lubricious catheters |
US5370640A (en) * | 1993-07-01 | 1994-12-06 | Kolff; Jack | Intracorporeal catheter placement apparatus and method |
US5972416A (en) * | 1993-11-10 | 1999-10-26 | Mentor Corporation | Bipolar electrosurgical instrument and method for making the instrument |
US5824072A (en) * | 1993-11-15 | 1998-10-20 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
US5443505A (en) * | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
US5766242A (en) * | 1993-11-15 | 1998-06-16 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
US5547473A (en) * | 1994-05-12 | 1996-08-20 | Syntec, Inc. | Pneumatic vitrectomy for retinal attachment |
US5487725A (en) * | 1994-05-12 | 1996-01-30 | Syntec, Inc. | Pneumatic vitrectomy for retinal attachment |
US5545153A (en) * | 1994-08-15 | 1996-08-13 | A.V.I. - Advanced Visual Instruments, Inc. | Adjustable miniature panoramic illumination and infusion system for retinal surgery |
US5952378A (en) * | 1994-08-24 | 1999-09-14 | Pharmacia & Upjohn Ab | Methods and means for drug administration |
US5860923A (en) * | 1995-01-30 | 1999-01-19 | Cardiovascular Concepts, Inc. | Lesion measurement catheter and method |
US6036678A (en) * | 1995-02-28 | 2000-03-14 | Photogenesis, Inc. | Method for preparation and transplantation of planar implants and surgical instrument therefor |
US6468283B1 (en) * | 1995-05-14 | 2002-10-22 | Optonol, Ltd. | Method of regulating pressure with an intraocular implant |
US6544249B1 (en) * | 1996-11-29 | 2003-04-08 | The Lions Eye Institute Of Western Australia Incorporated | Biological microfistula tube and implantation method and apparatus |
US5929111A (en) * | 1996-12-18 | 1999-07-27 | Alcon Laboratories, Inc. | A-seco steroids effective at treating ophthalmic pathological neovascularization and controlling intraocular pressure |
US6142990A (en) * | 1997-02-15 | 2000-11-07 | Heidelberg Engineering Optische Messsysteme Gmbh | Medical apparatus, especially for reducing intraocular pressure |
US6102895A (en) * | 1997-09-30 | 2000-08-15 | Cortella; Julian M. | Digital fluid delivery and aspiration apparatus with mechanical de-amplifier |
US6149931A (en) * | 1997-10-27 | 2000-11-21 | The Regents Of The University Of California | Methods and pharmaceutical compositions for the closure of retinal breaks |
US6156042A (en) * | 1997-11-17 | 2000-12-05 | Aramant; Robert B. | Retinal tissue implantation instrument |
US6402734B1 (en) * | 1998-07-02 | 2002-06-11 | Jeffrey N. Weiss | Apparatus and method for cannulating retinal blood vessels |
US6024719A (en) * | 1998-07-06 | 2000-02-15 | Morris; Robert E | Method and apparatus for performing surgery inside the human retina using fluidic internal limiting membrane (ILM) seperation (FILMS) |
US6378526B1 (en) * | 1998-08-03 | 2002-04-30 | Insite Vision, Incorporated | Methods of ophthalmic administration |
US6397849B1 (en) * | 1998-08-03 | 2002-06-04 | Insite Vision Incorporated | Methods of ophthalmic administration |
US6112747A (en) * | 1998-11-06 | 2000-09-05 | Jones; Jesse M. | Method of sterilizing females |
US20030236484A1 (en) * | 1999-04-26 | 2003-12-25 | Gmp Vision Solutions, Inc. | Inflatable device and method for treating glaucoma |
US7220238B2 (en) * | 1999-04-26 | 2007-05-22 | Gmp Vision Solutions, Inc. | Shunt device and method for treating glaucoma |
US6524275B1 (en) * | 1999-04-26 | 2003-02-25 | Gmp Vision Solutions, Inc. | Inflatable device and method for treating glaucoma |
US6413245B1 (en) * | 1999-10-21 | 2002-07-02 | Alcon Universal Ltd. | Sub-tenon drug delivery |
US20010053873A1 (en) * | 1999-11-24 | 2001-12-20 | Hansgeorg Schaaf | Device for improving drainage of the aqueous humor within the eye of a living being |
US7217263B2 (en) * | 2000-01-03 | 2007-05-15 | The Johns Hopkins University | Device and method for manual retinal vein catheterization |
US6726676B2 (en) * | 2000-01-05 | 2004-04-27 | Grieshaber & Co. Ag Schaffhausen | Method of and device for improving the flow of aqueous humor within the eye |
US20040039401A1 (en) * | 2000-03-31 | 2004-02-26 | Chow Alan Y. | Implant instrument |
US20060084943A1 (en) * | 2000-04-05 | 2006-04-20 | Biocardia, Inc. | Implant delivery catheter system and methods for its use |
US20010044595A1 (en) * | 2000-05-02 | 2001-11-22 | Wilson-Cook Medical, Inc. | Introducer apparatus with eversible sleeve |
US6668190B2 (en) * | 2000-06-16 | 2003-12-23 | Wayne State University | Method and apparatus for activating molecules to stimulate neurological tissue |
US6692759B1 (en) * | 2000-06-28 | 2004-02-17 | The Regents Of The University Of California | Methods for preparing and using implantable substance delivery devices |
US20020026176A1 (en) * | 2000-08-30 | 2002-02-28 | Varner Signe Erickson | Devices for intraocular drug delivery |
US20020169468A1 (en) * | 2001-01-09 | 2002-11-14 | J.David Brown | Glaucoma treatment device and method |
US7276019B2 (en) * | 2001-02-22 | 2007-10-02 | Retinalabs, Inc. | Ophthalmic treatment apparatus |
US6875165B2 (en) * | 2001-02-22 | 2005-04-05 | Retinalabs, Inc. | Method of radiation delivery to the eye |
US7122042B2 (en) * | 2001-03-15 | 2006-10-17 | Lorusso Frank J | Apparatuses and methods for transcleral cautery and subretinal drainage |
US20040254520A1 (en) * | 2001-04-07 | 2004-12-16 | Eric Porteous | Coil implant for glaucoma treatment |
US20030014036A1 (en) * | 2001-06-12 | 2003-01-16 | Varner Signe Erickson | Reservoir device for intraocular drug delivery |
US6766817B2 (en) * | 2001-07-25 | 2004-07-27 | Tubarc Technologies, Llc | Fluid conduction utilizing a reversible unsaturated siphon with tubarc porosity action |
US20040050392A1 (en) * | 2001-08-28 | 2004-03-18 | Hosheng Tu | Glaucoma stent for treating glaucoma and methods of use |
US7331984B2 (en) * | 2001-08-28 | 2008-02-19 | Glaukos Corporation | Glaucoma stent for treating glaucoma and methods of use |
US20040249404A1 (en) * | 2001-11-22 | 2004-12-09 | Haefliger Eduard Anton | Device and method for the performance of ophthalmological operations |
US6908476B2 (en) * | 2001-12-21 | 2005-06-21 | Alcon Grieshaber Ag | Micro surgical cutting instrument configured as scissors |
US7189245B2 (en) * | 2002-02-14 | 2007-03-13 | Photogenesis, Inc. | Subretinal implantation device and surgical cannulas for use therewith |
US7247702B2 (en) * | 2002-02-28 | 2007-07-24 | The Penn State Research Foundation | Periocular drug delivery for diabetic retinopathy |
US7867186B2 (en) * | 2002-04-08 | 2011-01-11 | Glaukos Corporation | Devices and methods for treatment of ocular disorders |
US20040015140A1 (en) * | 2002-07-19 | 2004-01-22 | Shields Milton B. | Uveoscleral drainage device |
US7316676B2 (en) * | 2002-08-20 | 2008-01-08 | Gholam A. Peyman | Treatment of retinal detachment |
US20040039253A1 (en) * | 2002-08-20 | 2004-02-26 | Peyman Gholam A. | Treatment of retinal detachment |
US7699882B2 (en) * | 2002-09-17 | 2010-04-20 | Iscience Interventional Corporation | Apparatus and method for surgical bypass of aqueous humor |
US7141048B1 (en) * | 2002-10-17 | 2006-11-28 | Alcon, Inc. | Vitreoretinal instrument |
US7285107B1 (en) * | 2002-10-17 | 2007-10-23 | Alcon, Inc. | Vitreoretinal instrument |
US7285255B2 (en) * | 2002-12-10 | 2007-10-23 | Ecolab Inc. | Deodorizing and sanitizing employing a wicking device |
US20060200097A1 (en) * | 2003-01-24 | 2006-09-07 | Doheny Retina Institute | Reservoirs with subretinal cannula for subretinal drug delivery |
US20040199130A1 (en) * | 2003-04-03 | 2004-10-07 | Chornenky Victor I. | Apparatus and method for treatment of macular degeneration |
US7273445B2 (en) * | 2003-04-30 | 2007-09-25 | Board Of Trustees Of The University Of Illinois | Intraocular brachytherapy device and method |
US7207980B2 (en) * | 2004-01-23 | 2007-04-24 | Iscience Surgical Corporation | Composite ophthalmic microcannula |
US20050171507A1 (en) * | 2004-01-23 | 2005-08-04 | Christian Jeffrey J. | Composite ophthalmic microcannula |
US20070244520A1 (en) * | 2004-04-19 | 2007-10-18 | Searete Llc | Lumen-traveling biological interface device and method of use |
US20060110428A1 (en) * | 2004-07-02 | 2006-05-25 | Eugene Dejuan | Methods and devices for the treatment of ocular conditions |
US20070083221A1 (en) * | 2005-10-12 | 2007-04-12 | Sismed, Llc | Precision trephine |
US20070239066A1 (en) * | 2006-01-25 | 2007-10-11 | Laham Roger J | Devices and methods for tissue transplant and regeneration |
Cited By (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9827143B2 (en) | 1999-04-26 | 2017-11-28 | Glaukos Corporation | Shunt device and method for treating ocular disorders |
US10568762B2 (en) | 1999-04-26 | 2020-02-25 | Glaukos Corporation | Stent for treating ocular disorders |
US9492320B2 (en) | 1999-04-26 | 2016-11-15 | Glaukos Corporation | Shunt device and method for treating ocular disorders |
US10492950B2 (en) | 1999-04-26 | 2019-12-03 | Glaukos Corporation | Shunt device and method for treating ocular disorders |
US10485702B2 (en) | 2000-04-14 | 2019-11-26 | Glaukos Corporation | System and method for treating an ocular disorder |
US9993368B2 (en) | 2000-04-14 | 2018-06-12 | Glaukos Corporation | System and method for treating an ocular disorder |
US9572963B2 (en) | 2001-04-07 | 2017-02-21 | Glaukos Corporation | Ocular disorder treatment methods and systems |
US9987472B2 (en) | 2001-04-07 | 2018-06-05 | Glaukos Corporation | Ocular implant delivery systems |
US10828473B2 (en) | 2001-04-07 | 2020-11-10 | Glaukos Corporation | Ocular implant delivery system and methods thereof |
US10406029B2 (en) | 2001-04-07 | 2019-09-10 | Glaukos Corporation | Ocular system with anchoring implant and therapeutic agent |
US10285856B2 (en) | 2001-08-28 | 2019-05-14 | Glaukos Corporation | Implant delivery system and methods thereof for treating ocular disorders |
US10485701B2 (en) | 2002-04-08 | 2019-11-26 | Glaukos Corporation | Devices and methods for glaucoma treatment |
US9636254B2 (en) | 2006-06-30 | 2017-05-02 | Aquesys, Inc. | Systems for reducing pressure in an organ |
US20100100104A1 (en) * | 2006-06-30 | 2010-04-22 | Aquesys, Inc. | Systems for reducing pressure in an organ |
US10085884B2 (en) | 2006-06-30 | 2018-10-02 | Aquesys, Inc. | Intraocular devices |
US20110118745A1 (en) * | 2006-06-30 | 2011-05-19 | Aquesys, Inc. | Methods, systems and apparatus for relieving pressure in an organ |
US20100121249A1 (en) * | 2006-06-30 | 2010-05-13 | Aquesys, Inc. | Methods for reducing pressure in an organ |
US10828195B2 (en) | 2006-11-10 | 2020-11-10 | Glaukos Corporation | Uveoscleral shunt and methods for implanting same |
US9962290B2 (en) | 2006-11-10 | 2018-05-08 | Glaukos Corporation | Uveoscleral shunt and methods for implanting same |
US11426306B2 (en) | 2009-05-18 | 2022-08-30 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
US9283116B2 (en) | 2010-11-15 | 2016-03-15 | Aquesys, Inc. | Intraocular shunt deployment device |
US10842671B2 (en) | 2010-11-15 | 2020-11-24 | Aquesys, Inc. | Intraocular shunt placement in the suprachoroidal space |
US9326891B2 (en) | 2010-11-15 | 2016-05-03 | Aquesys, Inc. | Methods for deploying intraocular shunts |
US9192516B2 (en) | 2010-11-15 | 2015-11-24 | Aquesys, Inc. | Intraocular shunt placement |
US10004638B2 (en) | 2010-11-15 | 2018-06-26 | Aquesys, Inc. | Intraocular shunt delivery |
US9095411B2 (en) | 2010-11-15 | 2015-08-04 | Aquesys, Inc. | Devices for deploying intraocular shunts |
US10940040B2 (en) | 2010-11-15 | 2021-03-09 | Aquesys, Inc. | Intraocular shunt placement |
US9017276B2 (en) | 2010-11-15 | 2015-04-28 | Aquesys, Inc. | Shunt placement through the sclera |
US9693901B2 (en) | 2010-11-15 | 2017-07-04 | Aquesys, Inc. | Shunt placement through the sclera |
US9393153B2 (en) | 2010-11-15 | 2016-07-19 | Aquesys, Inc. | Methods for intraocular shunt placement |
US8974511B2 (en) | 2010-11-15 | 2015-03-10 | Aquesys, Inc. | Methods for treating closed angle glaucoma |
US9877866B2 (en) | 2010-11-15 | 2018-01-30 | Aquesys, Inc. | Intraocular shunt placement |
US8852256B2 (en) | 2010-11-15 | 2014-10-07 | Aquesys, Inc. | Methods for intraocular shunt placement |
US8828070B2 (en) | 2010-11-15 | 2014-09-09 | Aquesys, Inc. | Devices for deploying intraocular shunts |
US9980854B2 (en) | 2010-11-15 | 2018-05-29 | Aquesys, Inc. | Shunt placement through the sclera |
US8801766B2 (en) | 2010-11-15 | 2014-08-12 | Aquesys, Inc. | Devices for deploying intraocular shunts |
US10307293B2 (en) | 2010-11-15 | 2019-06-04 | Aquesys, Inc. | Methods for intraocular shunt placement |
US10245178B1 (en) | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
US9095413B2 (en) | 2011-12-08 | 2015-08-04 | Aquesys, Inc. | Intraocular shunt manufacture |
US8852136B2 (en) * | 2011-12-08 | 2014-10-07 | Aquesys, Inc. | Methods for placing a shunt into the intra-scleral space |
US9883969B2 (en) | 2011-12-08 | 2018-02-06 | Aquesys, Inc. | Intrascleral shunt placement |
US20130150770A1 (en) * | 2011-12-08 | 2013-06-13 | Aquesys, Inc. | Methods for placing a shunt into the intra-scleral space |
US9592154B2 (en) | 2011-12-08 | 2017-03-14 | Aquesys, Inc. | Intraocular shunt manufacture |
US10314743B2 (en) | 2011-12-08 | 2019-06-11 | Aquesys, Inc. | Intraocular shunt manufacture |
US9271869B2 (en) | 2011-12-08 | 2016-03-01 | Aquesys, Inc. | Intrascleral shunt placement |
US8765210B2 (en) | 2011-12-08 | 2014-07-01 | Aquesys, Inc. | Systems and methods for making gelatin shunts |
US9113994B2 (en) | 2011-12-08 | 2015-08-25 | Aquesys, Inc. | Intraocular shunt manufacture |
US10080682B2 (en) | 2011-12-08 | 2018-09-25 | Aquesys, Inc. | Intrascleral shunt placement |
US10271989B2 (en) | 2012-03-26 | 2019-04-30 | Glaukos Corporation | System and method for delivering multiple ocular implants |
US11944573B2 (en) | 2012-03-26 | 2024-04-02 | Glaukos Corporation | System and method for delivering multiple ocular implants |
US9554940B2 (en) | 2012-03-26 | 2017-01-31 | Glaukos Corporation | System and method for delivering multiple ocular implants |
US11197780B2 (en) | 2012-03-26 | 2021-12-14 | Glaukos Corporation | System and method for delivering multiple ocular implants |
US20130296694A1 (en) * | 2012-05-04 | 2013-11-07 | The Cleveland Clinic Foundation | Surgical instruments for oct assisted procedures |
US10195079B2 (en) | 2013-02-19 | 2019-02-05 | Aquesys, Inc. | Adjustable intraocular implant |
US9125723B2 (en) | 2013-02-19 | 2015-09-08 | Aquesys, Inc. | Adjustable glaucoma implant |
US10159600B2 (en) | 2013-02-19 | 2018-12-25 | Aquesys, Inc. | Adjustable intraocular flow regulation |
US10195078B2 (en) | 2013-02-19 | 2019-02-05 | Aquesys, Inc. | Adjustable intraocular flow regulation |
US10524959B2 (en) | 2013-02-27 | 2020-01-07 | Aquesys, Inc. | Intraocular shunt implantation methods and devices |
US9610195B2 (en) | 2013-02-27 | 2017-04-04 | Aquesys, Inc. | Intraocular shunt implantation methods and devices |
US10285853B2 (en) | 2013-03-15 | 2019-05-14 | Glaukos Corporation | Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye |
US10188551B2 (en) | 2013-03-15 | 2019-01-29 | Glaukos Corporation | Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye |
US11253394B2 (en) | 2013-03-15 | 2022-02-22 | Dose Medical Corporation | Controlled drug delivery ocular implants and methods of using same |
US9592151B2 (en) | 2013-03-15 | 2017-03-14 | Glaukos Corporation | Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye |
US10517759B2 (en) | 2013-03-15 | 2019-12-31 | Glaukos Corporation | Glaucoma stent and methods thereof for glaucoma treatment |
US11559430B2 (en) | 2013-03-15 | 2023-01-24 | Glaukos Corporation | Glaucoma stent and methods thereof for glaucoma treatment |
US11523938B2 (en) | 2013-03-15 | 2022-12-13 | Glaukos Corporation | Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye |
US9808373B2 (en) | 2013-06-28 | 2017-11-07 | Aquesys, Inc. | Intraocular shunt implantation |
US10369048B2 (en) | 2013-06-28 | 2019-08-06 | Aquesys, Inc. | Intraocular shunt implantation |
US11298264B2 (en) | 2013-06-28 | 2022-04-12 | Aquesys, Inc. | Intraocular shunt implantation |
US9585790B2 (en) | 2013-11-14 | 2017-03-07 | Aquesys, Inc. | Intraocular shunt inserter |
US10653555B2 (en) | 2013-11-14 | 2020-05-19 | Aquesys, Inc. | Intraocular shunt insertion techniques |
US10470928B2 (en) | 2013-11-14 | 2019-11-12 | Aquesys, Inc. | Intraocular shunt inserter |
US11938059B2 (en) | 2013-11-14 | 2024-03-26 | Aquesys, Inc. | Intraocular shunt insertion techniques |
US10959941B2 (en) | 2014-05-29 | 2021-03-30 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
US11612517B2 (en) | 2015-06-03 | 2023-03-28 | Aquesys, Inc. | Ab externo intraocular shunt placement |
US10470927B2 (en) | 2015-06-03 | 2019-11-12 | Aquesys, Inc. | AB externo intraocular shunt placement |
US10463537B2 (en) | 2015-06-03 | 2019-11-05 | Aquesys Inc. | Ab externo intraocular shunt placement |
US11925578B2 (en) | 2015-09-02 | 2024-03-12 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
US11564833B2 (en) | 2015-09-25 | 2023-01-31 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
US11318043B2 (en) | 2016-04-20 | 2022-05-03 | Dose Medical Corporation | Bioresorbable ocular drug delivery device |
US10667947B2 (en) | 2016-06-02 | 2020-06-02 | Aquesys, Inc. | Intraocular drug delivery |
US11116625B2 (en) | 2017-09-28 | 2021-09-14 | Glaukos Corporation | Apparatus and method for controlling placement of intraocular implants |
US11376040B2 (en) | 2017-10-06 | 2022-07-05 | Glaukos Corporation | Systems and methods for delivering multiple ocular implants |
USD938585S1 (en) | 2017-10-27 | 2021-12-14 | Glaukos Corporation | Implant delivery apparatus |
USD901683S1 (en) | 2017-10-27 | 2020-11-10 | Glaukos Corporation | Implant delivery apparatus |
USD846738S1 (en) | 2017-10-27 | 2019-04-23 | Glaukos Corporation | Implant delivery apparatus |
US11246753B2 (en) | 2017-11-08 | 2022-02-15 | Aquesys, Inc. | Manually adjustable intraocular flow regulation |
US10952898B2 (en) | 2018-03-09 | 2021-03-23 | Aquesys, Inc. | Intraocular shunt inserter |
US11135089B2 (en) | 2018-03-09 | 2021-10-05 | Aquesys, Inc. | Intraocular shunt inserter |
WO2020121061A3 (en) * | 2018-12-13 | 2020-07-30 | Ioptima Ltd. | Methods and systems for laser assisted technology for minimally-invasive ab-interno glaucoma surgery |
Also Published As
Publication number | Publication date |
---|---|
WO2004026347A9 (en) | 2004-07-22 |
CA2499094A1 (en) | 2004-04-01 |
EP1539066A4 (en) | 2008-05-21 |
WO2004026347A2 (en) | 2004-04-01 |
AU2003273339B2 (en) | 2008-08-14 |
WO2004026347A3 (en) | 2004-06-03 |
AU2003273339A1 (en) | 2004-04-08 |
CA2499094C (en) | 2011-07-19 |
JP2005538804A (en) | 2005-12-22 |
US20060155300A1 (en) | 2006-07-13 |
JP4606878B2 (en) | 2011-01-05 |
EP1539066B1 (en) | 2012-11-07 |
US7699882B2 (en) | 2010-04-20 |
EP1539066A2 (en) | 2005-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7699882B2 (en) | Apparatus and method for surgical bypass of aqueous humor | |
AU2005240123B2 (en) | Apparatus and method for surgical enhancement of aqueous humor drainage | |
US11559430B2 (en) | Glaucoma stent and methods thereof for glaucoma treatment | |
US20240074900A1 (en) | Ocular implant with stiffness qualities, methods of implantation and system | |
US10485701B2 (en) | Devices and methods for glaucoma treatment | |
JP5438031B2 (en) | Fluid passage opening device and method | |
US20130281910A1 (en) | Ocular implant system | |
US20170042736A9 (en) | Delivery System and Method of Use for the Eye | |
JP4606878B6 (en) | Device for surgical bypass of aqueous humor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |